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Abstract
Amgen Inc. currently manufactures, formulates and fills substantially all of their global drug product units
in a single primary facility ("Site 1A"). Concerned about the inherent risks posed by the geographic
concentration of these activities, Amgen has decided to acquire a new international Risk Mitigation Site
("RMS"), expand existing bulk manufacturing infrastructure at Site 1A, and construct a new formulation
and filling facility colocated with Site 1A ("Site IB").
Bringing both sites online in the near future will create a novel operational challenge for Amgen, as it will
present a broad range of formulation/fill production allocation decisions that did not previously exist. If
per-unit costs (production, logistics, etc.) were considered to be typically higher at either RMS or Site
1A/B, an unconstrained optimization model might suggest filling/finishing all product at whichever site
has the lowest average cost. However, we assume that RMS should be able to ramp up to full capacity
within 3 months of an adverse occurrence at Site 1A. This translates to a minimum product flow
constraint through RMS, irrespective of per unit costs, that will keep the facility sufficiently staffed to
prepare for a fast ramp-up. Furthermore, helping Amgen mitigate the risks of geographic concentration,
RMS may typically produce only a portion of global demand for any product.
Given this situation, this thesis develops a product allocation strategy that will:
1) minimize the financial cost of filling various quantities of drug product at the new facility, yet
2) maintain at RMS the expertise required begin manufacturing all drugs in a short period of time.
A mixed-integer linear program ("MILP") was developed to capture variable costs of the formulation &
fill process for each drug product ("DP") and market combination. The objective of this model is to
minimize total supply chain costs subject to meeting market demand and maintaining a sufficient amount
of product flow through the RMS facility. The analysis assumes that the decision to develop fill capacity
at both RMS and Site lB is complete and that both facilities will be licensed to fill all products that
currently run through Site 1A (i.e. capital investment decisions will not be analyzed in this study).
The outcome of this study is a product allocation strategy that minimizes network costs as well as a tool
that will enable Amgen to solve for minimal network costs under additional future scenarios.
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1 Introduction
1.1 A New Supply Chain Reality: Project Background
On March 11, 2011, the Wall Street Journal reported the following:
Amgen Inc. (AMGN) is buying a ... manufacturing facility from Pfizer Inc. (PFE) for an
undisclosed amount.
The deal for the plant ... is expected to close in the second quarter. Pfizer had disclosed
its plans to exit the site last May in a restructuring of its global manufacturing
operations...
... Amgen will use the site to "formulate and fill" its biologic drugs, which means getting
the proper dose in a bottle or syringe along with packaging and labeling.
It plans to eventually expand manufacturing at the location. The move allows the
company to expand its formulating and filling capabilities beyond its [primary] plant, and
will "ensure continuity of supply" of its products, the Amgen spokeswoman said. (Gryta
2011)
The same day, Amgen's stock closed at $53.53, up 3.22% for the day, well above the same day close for
the DJIA and Nasdaq (0.56% and 0.97%) respectively. Ranking days by Amgen's market-adjusted daily
return reveals that this announcement is one of the six most impactful events in the past two years,
alongside the announcement of the FDA's announcement of effective mid-trial results for and ultimate
approval of denosumab, Amgen's ninth and most recent major product. This market response suggests
that Amgen's decision is both significant in nature and well received by investors and Wall Street
analysts.
On the day following the announcement of the new site acquisition, a second newspaper covered the
story in further depth, reporting:
"As we expand internationally, the [new] site will help us deliver a growing supply of
Amgen medicines for patients worldwide," said Madhu Balachandran, senior vice-
president, Amgen Manufacturing.(Coyle 2011)
Together, these stories point toward two fundamental operational challenges that Amgen seeks to address
through the acquisition of the RMS:
1) an increasing complexity of production-distribution functions due to international expansion
and resulting variety of product configurations (formulations, presentations and packages),
and
2) the need to design a supply chain and production process robust enough to ensure continuity
of supply, even in the face of "Black Swan" events, such as the recent earthquakes in Haiti
and Japan.
The additional formulation and fill facility is geographically closer to new European markets (potentially
addressing the first challenge) and quite distant from the current primary formulation and fill operations at
Site 1A (potentially addressing the second challenge).
At the same time, the integration of this site into Amgen's production network presents its own
challenges. Most notably, whereas Amgen once formulated and filled virtually all drug product ("DP") at
Site 1A, the company must now decide what products to formulate and fill in what quantity at each site.
Different manufacturing and distribution constraints (e.g. facility steel capacity) as well as costs (e.g.
variable labor, transportation) at sites and between sites suggest that there is a significant financial benefit
to optimizing production-distribution planning. Although Amgen only has nine major product families, it
has over 75 different formulations and presentations (e.g. vial or pre-filled syringe), and hundreds of
UPC's due to the need to package in different languages or test for different regulatory bodies.
This thesis develops a methodology to address how Amgen efficiently integrates the RMS into global
operations as well as a tool to apply this methodology. The following sections describe the development
of a Mixed Integer Linear Program ("MILP") that models Amgen's production-distribution network. We
then apply this model to optimize production-distribution decisions by solving for the lowest network
cost, subject to implied constraints and under various scenarios and/or assumptions. The concluding
sections of this thesis discuss the strategic implications of the results of this model, as well as the
limitations of this analytical approach.
1.2 Thesis Structure
The intended audience of this thesis has some familiarity with supply chain design and linear
optimization, but little or no prior exposure to biotechnology. Thus, Chapter 2 includes a general
background on biotechnology and the biopharmaceutical industry, an introduction to Amgen, and a high-
level view of their production-distribution network so as to inform the later sections.
The literature review presented in Chapter 3 covers three distinct subsets of relevant literature. The
first is a brief overview of prior relevant theses written by Leaders for Global Operations ("LGO")
fellows, in the three years that Amgen has been a partner company of the LGO program. The purpose of
this section is to present the context of other operations challenges on which Amgen has recently worked
as well as point toward the operational maturing that Amgen has undergone in recent years. The second
portion covers general issues in production-distribution system design. This section also outlines findings
from some of the most salient prior reviews of literature in this field. The third and final section looks at
prior theoretical papers and case studies in which a MILP was developed to solve a production-
distribution optimization problem and compares these to the approach of this thesis.
Following the literature review, Chapter 4 outlines the problem statement and methodology of this
study. A detailed MILP is presented and specific aspects are discussed in detail. This section also covers
the data sources that were used to populate the model, as well as a detailed description of data-
preprocessing steps and assumptions.
Chapter 5 analyzes the results of the model, discussing how different sets of assumptions led to
different outcomes and distills key recommendations to management from the most salient findings.
Chapter 6 concludes by reviewing the findings and recommendations and recommendations of this
thesis. In addition, this section covers the issues of next steps and implementation, future work that
Amgen can pursue in this field, and the limitations of the analytical approach employed.
2 Background
2.1 Biopharmaceutical Industry
Biotechnology is the branch of molecular biology that studies the use of microorganisms to perform
specific industrial processes (Miller 2006). Beginning in the 1970s in Northern California,
biotechnology has since grown into a global industry comprised of several sectors including healthcare,
agriculture, and biodefense. Typical biotechnology processes work by inserting recombinant DNA, or
DNA that has been modified through genetic engineering, into host cells. Using this information, host
cells will then create recombinant proteins, the product of the biotechnology process (Amgen 2009).
The biopharmaceuticals industry is the branch of biotechnology that specializes in developing human
therapeutics. The three primary functions of the biopharmaceutical industry are drug discovery, drug
development and manufacturing. Drug discovery involves identification and validation of targets, or
molecules that play important roles in a current unmet medical need, as well as screening processes to
better understand the associated biomolecular pathway and ultimately design of a drug that will
beneficially interact with the molecular target (Amgen 2009).
Drug development begins with preclinical studies in lab animals, followed by three phases of clinical
trials that are closely monitored by either the Food and Drug Administration, or FDA (in the United
States) or European Medicines Agency, or EMEA (in Europe). The three phases require the applicant
company to evaluate the drug to determine, in sequence, safety, efficacy and effectiveness. While most
investigational drugs fail in phase 2 trials, phase 3 trials are the most expensive and time-consuming,
often requiring over two years to complete. During phase 3 an applicant company must show that the
drug is more effective than current drugs on the market and is safe over a long period of time. Upon
successful completion of phase 3 trials, a company completes a Biologic License Application with the
relevant regulatory agency, after which time it can market the drug to patients (Amgen 2009).
The biopharmaceutical production process is described in detail in Section 2.3 below.
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2.2 Amgen Inc.
Amgen, originally called American Molecular Genetics, was founded in 1980 as one of the first
biotechnology companies and has since grown into a Fortune 500 company and one of the largest in
biotech.
Amgen is a company of large impact through few products. Two of Amgen's early products,
Epogen@ and Neupogen@ became the first biopharmaceuticals to gross over $1B in annual revenues,
known as blockbuster drugs within the industry. Amgen continues to produce Epogen@ as well as
Aranesp@, both erythropoietic-stimulating agent ("ESA") used to stimulate the production of red blood
cells and treat anemia. Neulasta@ and Neupogen@ both stimulate the production of specific white blood
cells, frequently a critical post-chemotherapy treatment, and together account for over $4.5B of Amgen's
annual sales. Amgen acquired the rights to market and produce Enbrel@, a leading anti-inflammatory
drug used to treat rheumatoid arthritis, when they purchased Immunex in 2002 (Amgen 2009). Together
the above drugs make up over 90% of Amgen's annual revenues as shown in Table 1 Table Ibelow.
2009
A ranespo ........................................... $ 2,652
EPOG EN* .......................................... 2,569
Neulasta*/NEUPOGEN* .............................. 4,643
EN BREL ........................................... 3.493
Sensipar* ........................................... 651
O ther .............................................. 343
Total product sales ............................... $14,351
Total U.S. ........................................ $11.135
Total International .. .................................. 3,216
Total product sales ............................... $14,351
Table 1. Amgen 2009 Revenues by Product (Amgen 2009)
Other products include Sensipar@, used to treat secondary hyperparathyroidism in patients on
dialysis, Vectibix@, a specific cancer treatment, and Nplate@, a platelet producer, and two new
medications based on the denosumab monoclonal antibody, Prolia@ for postmenopausal osteoporosis and
XGEVA@ for skeletal-related events from solid tumors (Amgen 2009).
Amgen primarily manufactures its products in the United States and a nearby territory, but it also has
a major European packaging facility as well as a manufacturing partnership with Kirin Holdings in Japan.
The market for drugs, however is truly global: Amgen sells its drugs in 38 countries outside the United
States, including Canada, Japan, Brazil, India, Hong Kong, Australia, New Zealand, the U.A.E., and
almost all of Europe (Amgen 2009, 2011).
2.3 Biotechnology Production-Distribution Process Overview
Before developing a detailed mathematical model of Amgen's production and distribution processes,
it is useful to present a basic overview of the processes.
Thefirst phase of biotechnology drug production is bulk manufacturing. The first stage of this
process, scale up, begin with the cracking of a vial containing a small number of dormant cells genetically
engineered to create a specific protein that will eventually be formulated into drug product. Scale up
begins with activation of the dormant cells in a small and progressively larger beaker. From that point
throughout the entire bulk manufacturing process, the concentrations of glucose, lactic acid and other
process by-products are monitored to maintain optimal cell replication and durability.
After 10-12 days of scale up, cells spend approximately 5-7 days in a wave bioreactor, which is a
rocking mechanism that contains a large (up to 1 OOOL) low density polyethylene/ethylene vinyl acetate
(LDPE/EVA) copolymer bag that is pre-sterilized, irradiated and designed for single use. The benefits of
wave bioreactors include their ability to scale from relatively low volumes to much larger volumes and
the fact that they induce agitation and oxygen transfer by rocking the LDPE/EVA bag rather than by more
invasive means such as mechanical mixing or gas sparging.
After the wave bioreactor, the mixture is transferred to a series of three to four stainless steel
bioreactors for the large-scale process. The sizes of these bioreactors are largely dependent on the facility
(e.g. the largest in a commercial manufacturing facility may be 15k L, compared to 2k L for a clinical
manufacturing facility). In a typical three bioreactor setup, the mixture may spend 3 days in the first two
bioreactors (60L and 300L in Amgen's clinical facility), followed by 11 days in the final 2k L bioreactor.
In a commercial setting, this size may be the second to last step, in which case it would spend 3-4 days
there following by 11-12 days in the largest bioreactor.
Altogether, the above steps are referred to as upstream manufacturing and comprise 32-40 days. The
remaining steps, known as downstream manufacturing are performed after the concentration of cells and
protein have reached their optimal level. These steps collectively take approximately one week and
include centrifuge, purification, viral inactivation, multiple chromatography steps, viralfiltration, ultra-
filtration/di-filtration ("UFDF"), andfinalfiltration. The output of this process is typically carboys or
cryo-vessels of bulk drug substance ("DS") or drug substance intermediate ("DSI").
The secondphase of biotechnology drug production is known as formulation and fill. This process,
which is sometime but need not be collocated with bulk manufacturing, the DS is formulated to the FDA-
approved concentrations (typically through dilution with a non-reactive, benign media), and then
dispensed by a sterile needle-filling machine into a final container. The final container, or presentation,
depends on the market need, but it is typically one of three: a vial, a lyophilized vial, or a pre-filled
syringe ("PFS"). Lyophilization is the process by which a drug solution is freeze dried so that only the
protein remains in power form. The benefit of this process is that it typically results in a longer shelf-life
for the end product. However, it also requires more steps for the administrator of the drug, and can
sometimes lead to a more pronounced stinging feeling when the drug is administered. Once filled, the
drug is referred two as drug product ("DP"). Typically, inspection of the DP follows immediately, at
which point the vials or syringes are referred to as inspected drug product ("IDP").
The thirdphase of the production process is packaging. During this phase the IDP is packaged for
the end user. Typically multiple packaging configurations exist (e.g. kit or carton, top-load or side-load,
one-pack or five-pack). This combined with the multiplicity of packaging and insert languages in
international markets causes this step to be Amgen's key product differentiation step. For that reason, this
step is often postponed for international markets.
Thefinal phase of following the three production phases described above is distribution to customers.
Customers are often large scale health systems, hospital systems, pharmacies or medical services
providers. Depending on locations and distances, products are shipped via cargo ship, air freighter or
truck. Figure 1 shows an overview of the production-distribution process described here.
Process Nomenclature
Bulk manufacturing Formulation & Fill Packaging Distribution
Product Nomenclature throuahout Processes
DS/DSI 3 PD :I PD FDPDDrug Substance roductInspected Drug Finished DrugProduc Prodctuct(intermediate) Product Product
Figure 1. Biotechnology Production-Distribution Process Overview
From a logistics perspective, where these processes occur is almost as important as how they occur.
The bulk manufacturing phase actually occurs in a variety of places. Possibly partly due to the fact that
Amgen grew its product portfolio and manufacturing footprint through acquisition, the bulk
manufacturing process is the most geographically diverse. Although Amgen's primary facility
manufactures several drugs such as Aranesp, Neupogen, Neulasta, other drugs are bulk manufactured in
places such as West Greenwich, RI (Enbrel), Fremont, CA (Vectibix), and Longmont, CO (Epogen,
Nplate and Denosumab) (Amgen 2009).
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The formulation and fill step, by contrast is much more highly concentrated. With the exception of a
very small quantity of product, almost all of Amgen's DS and DSI is formulated and filled at Site IA. As
mentioned in the Wall Street Journal excerpt above, a desire to overcome this geographic concentration is
at least part of the rationale for the acquisition of the RMS.
The packaging step is also concentrated, but by end market rather than global production. Site 1A
handles almost all of the packaging for the US market (referred to as the North American Commercial
Organization or "NACO"), and the European packaging site ("Site 2") handles most of the packaging for
the European and other international markets (collectively referred to as the International Commercial
Organization or "ICO").
For the NACO markets, distribution is managed by Amgen's primary U.S.-based distribution center.
For ICO markets, Site 2 handles distribution as well. Figure 2 below gives a rough geographic picture of
where drug product is bulk manufactured, formulated, filled, packaged and distributed in Amgen's current
production-distribution system. A full profile of Amgen's geographic locations and processes at these
locations is provided in Appendix E.
Figure 2. Production Capabilities and Product Flows
Looking at the above Figure, the operational planning challenge that Amgen will face upon
expansion into a new formulation and fill facility is even more salient: as Site IA currently fulfills this
process for practically all of global demand, the formulation and fill scheduling can be optimized at the
facility level. Once a second plant is available, tradeoffs such as tax implications and transportation costs
will need to be considered as they could have a significant impact on the suggested product allocation.
3 Literature Review
This section covers three distinct subsets of relevant literature. The first is a brief overview of
relevant prior theses written by Leaders for Global Operations ("LGO") fellows. The second portion
covers general issues in production-distribution system design as well as several prior reviews of this
subject matter. The third and final section looks at prior theoretical papers and case studies in which a
MILP was developed to solve a production-distribution optimization problem.
3.1 Prior LGO Theses
Amgen began its partnership with the LGO program in 2008, and in the three years since that time
eleven theses have been completed. These theses can be roughly classified into three sub-groups:
production process improvement studies, new production process business cases, and broad-reaching
strategic managerial analyses.
Production process improvement studies were identified by the discussion of an existing process at
Amgen, as well as the goal of improving outcomes through continuous improvement or Lean
transformation. These theses include a high-level overview of the development of continuous
improvement methodologies within Amgen's Operations Improvement group (Villa 2008), an analysis of
the Amgen Process Excellence ("APEX") initiative (Coffey 2008), and a study of the impact that Lean
and Six Sigma tools had on the cycle time of the buffer solution preparation process at Amgen Freemont
("AFR") (Jay 2009).
Theses classified as new production process analyses or business cases either introduced a new
process or analyzed the impact a novel component would have on an existing process. New process
studies included an evaluation of drying technologies rather than cryopreservation for DS storage and
shipment (Vaudant 2008) and a case study on the implications of temporary markings on nude vials
(Hardy 2010). One thesis looked at the changes to manufacturing processes due to a novel component,
specifically the impact of novel filtration applications for the removal of protein aggregates from drug
solution (Hunnicutt 2008).
The remaining prior Amgen theses were classified as broad-reaching managerial analyses and are
most similar in context to this analysis. These theses are characterized by the analysis of an analytical
framework or decision tool that goes beyond the facility or production line unit of analysis. These studies
included a strategic sourcing framework for bulk manufacturing at Rhode Island (Pasenek 2008), an
analysis of the impact of Quality by Design principles on Amgen's commercialization process (Matthew
2009), and a case study how a greater cost focus affects the delivery of capital projects (Kristinsd6ttir
2008). Two recent theses in this group developed a recommendation for Amgen's future approach to
sourcing PFS components (Lee 2010), and an analytical framework to optimize Amgen's truck
distribution system and distribution center location selection (Sekar 2010).
Two general comments can be made about the prior work by LGO fellows at Amgen. First, the focus
of the analytical work tended to be more toward incremental process improvement rather than high-level
strategic change. This traditional preference for process improvement work can be seen in Figure 3
below, a word cloud that represents frequency of occurrence of non-trivial words in all prior LGO Amgen
theses. As can be seen in the figure, concepts related to manufacturing and process improvement are
most salient, whereas issues of supply and distribution occur with a lesser frequency and topics such as
simulation, optimization, and linear or mixed integer programming are not represented in prior LGO
research at Amgen.
AnEX analytia i result BDS w~j
.u cost new case Operatios o ntm St
soYcmgAmgen company prefillednar l imoringe Enbre'cles
pruction , mPlementatiok syrllngerp
potenta patient * up wicaew vies regulatioryimpact.
productsindpplpustry r product c"t" """U PrssidU t~lr~ o c me
coMPm.essdppyeleopinen I .. sraegbiophiaurmaceuticalris QbD - methodology rug business
tec I e s : dI tUrngdstribution
~aucc ipnpharmaceutica  improvement'
mangmentchangesfuturetprocessabietinhnI
growth ieons p l- manufacture don . iC i g
contnuous characterization Operat10nalwitn
hitlch efforts 'Pe"process developing research operations
well
Figure 3. Word Cloud - Frequency of Terms in Prior LGO Theses on Amgen'
A second finding from the LGO literature review is that, despite the traditional bias toward process
improvement work, the nature of work being performed at Amgen seems to be moving from realm of
production process toward a greater focus on strategic, company-wide issues. Figure 4 shows how
process improvement studies have diminished over the past few years, while theses with a more strategy
focus have grown in proportion. It is difficult to say whether this trend reflects the preferences of
companies or LGO fellows, but in either case, the outcome is apparent.
Strategic
Managerial
Analyses
New Process
Business Case
Production
Process
Imporvement
2008 2009 2010
(n=6) (n=2) (n=3)
Figure 4. Number of LGO Theses by Author's Classification & Year
Source: www.wordle.net. Note: The words "thesis," "Rhode," and "Island" were removed, along with commonly
occurring English articles, conjunctions and pronouns.
3.2 Production-Distribution System Design and Prior Reviews
This sub-section briefly reviews the literature related to production-distribution system design per se
as well as prior reviews of literature on this topic.
Shi and Gregory aim to classify different configurations of international manufacturing networks
(1998). The authors suggest that international manufacturing network systems have all of the complexity
of factory-based manufacturing systems (e.g. line capacity, technology, workforce and quality concerns)
as well as network issues (e.g. geographic dispersion, horizontal and vertical coordination and dynamic
capability building). In addressing these challenges, the authors claim that some organizations fail to
develop the capabilities of network learning (e.g. wider internal and external comparison, best practices
exchange and benchmarking) and thus become multi-domestic manufacturing rather than global
coordinated manufacturing organizations (Shi and Gregory 1998).
Thomas and Griffin (1996) come to a similar conclusion, stating that:
In the past, organizations have focused their efforts on making effective decisions within
a facility. In this case, the various functions of an organization, including assembly,
storage, and distribution are generally decoupled into their functional and geographic
components through buffers of large inventories. In this way, the complexity of the
decisions is reduced since each component is treated independently of the others.
Ignoring these component dependencies, however, can have costly consequences. This
becomes increasingly apparent with market globalization. As a result, firms are moving
from decoupled decision making processes toward more coordinated and integrated
design and control of all of their components in order to provide goods and services to the
customer at low cost and high service levels.
Thomas and Griffin proceed to review research on three modes of global management (buyer-vendor
coordination, production-distribution coordination and inventory-distribution coordination) and propose
the use of either mixed integer programming models or strategic planning models to effectively manage
these processes. The authors' conclusions include the claims that "long supply chains inhibit a firm's
ability to respond quickly to consumer requirements," that "knowledge of all value-added activities in the
supply chain is critical to coordinated modeling," and that "the single largest component of logistics cost
is transportation cost, often comprising over half of total logistics cost" (Thomas and Griffin 1996).
Although the first two are helpful to keep in mind in the case of biopharmaceutical production-
distribution processes, the third claim does not necessarily hold in this industry.
Diving deeper into the concept of transportation cost, Cooper presents the concept of value densities
(the value of product in relation to its weight and volume) and competition. His paper gives examples of
how low value density products (e.g. cement) are typical served by local catchment areas because
transportation is a large component to price. Products with high value densities (e.g. precious stones or
pharmaceuticals) have a much larger "logistics reach," but this reach can also be limited in highly
competitive markets (Cooper 1993).
In addition to the above studies, which conceptually frame the challenge Amgen faces as it expands
internationally, several other authors have provided exceptionally helpful reviews of the literature on
international supply chain planning. Bhatnagar, Chandra et al. (1993) produced one of the earliest of
these reviews, in which they classified coordination research into the same three categories as Thomas
and Griffin. They laid the groundwork for production-distribution research that was to following, stating
that:
the multi-plant coordination problem seeks to link together the production plans of
several manufacturing plants which are part of a vertically integrated firm, i.e., output
from one plant becomes an input into another plant. The objective of such coordination is
to achieve near optimal results on performance measures like total cost, manufacturing
lead time etc., for the entire organisation. Coordination efforts must model the impact that
production planning at one plant has on production planning at another plant. Such
models must also take into consideration uncertainties associated with both the demand
and the production processes (Bhatnagar, Chandra et al. 1993).
The authors then proceeded to identify three key challenges/objectives that continue to be important
today: nervousness (e.g. variability of demands on a plant due to internal issues such as scheduling
adjustments or forecast updates), lot sizing and safety stock.
Vidal and Goetschalckx (1997) go a step further than prior literature reviews, by also providing a very
helpful taxonomy of relevant optimization models including Geoffrion, Graves, et al. (1973), Brown,
Graves, et al. (1987), Cohen and Lee (1988), Cohen and Moon (1991), and Arntzen et al. (1995). In
summary, the authors conclude that:
The main drawback of these models is the fact that most uncertainties are not considered
in the formulations. In addition, there does not exist a formal and consistent way to
represent BOM constraints. Moreover, some international factors, such as exchange rates,
taxes, and duties are not fully described by the existing models ... We think that future
research should concentrate on the development of an overall global logistics framework,
supported by multiple inter-related models capable of representing qualitative factors and
uncertainties. This framework must include MIP models as a fundamental part, and
interact with management in a coordinated way to solve specific problems. However,
such a framework will remain a decision support tool, not a replacement of the decision-
maker function (Vidal and Goetschalckx 1997).
Beamon analyzed multiple supply chain models and performance measures developed in the literature
(1998). She summarized various objectives models were designed to optimize (cost, customer,
responsiveness, cost and customer responsiveness, cost and activity time) as well as the direction of this
optimization (e.g. minimize cost or maximize profit, minimize stockout probability or maximize available
system capacity). Ultimately, Beamon suggests that future research focus on the following four areas:
"(1) evaluation and development of supply chain performance measures, (2) development of models and
procedures to relate decision variables to the performance measures, (3) consideration of issues affecting
supply chain modeling, and (4) classification of supply chain systems to allow development of rules-of-
thumb or general techniques to aid in the design and analysis of manufacturing supply chains" (1998).
In a more recent literature review on the same subject, Peidro, Mula et al. (2009) outline four types of
supply chaining models (analytical, artificial intelligence, simulation and hybrid) under one to three types
of uncertainty (demand, process, and supply) to address three types of problems (strategic, tactical, and
operational). They find that most models address only one type of uncertainty (59.2%) whereas less than
10% address all three simultaneously. They suggest that artificial intelligence models are becoming more
dominant as supply chain modeling becomes increasingly complex. Finally, the authors provide several
suggestions for future work, including the development of more models that integrate multiple sources of
uncertainty and further empirical studies to compare the applicability of various modeling approaches.
3.3 MILP Formulations and Relevant Case Studies
Tsiakis and Papageorgiou (2008) employ a MILP to solve for optimal production allocation and
distribution in a generic three-echelon supply chain network comprised of production plants, distribution
centers and customer demand zones. The authors' model is the only reviewed that explicitly incorporates
tax and duty costs, which is specified for each product, plant and customer zone combination.
Additionally, this paper includes the concept of time utilization for plant maintenance as well as
changeovers. Their formulation allows for multiple campaigns for each product-production plant pair,
but a weakness is that this quantity is set as a parameter, thus constraining the possible set of solutions
considered by the MILP. Furthermore, although the authors consider unit production costs that vary by
product-plant pairs, the specified daily production rate varies by plant only, thus assuming all products are
produced at the same rate.
Thanh, Bostel et al. (2008) develop a MILP to optimize production-distribution in a four-echelon
supply chain (suppliers, plants, warehouses, customers). Allowing for multiple products, this model is
novel in that it includes fixed costs for supplier selection, facility opening/closing and election of specific
operating capacity expansion options. Addressing one of the weaknesses in Tsiakis and Papageorgiou
(2008), the authors allow for different per-unit workloads for each product-plant pair. On the other hand,
they do not account for changeover costs or the issue of production campaigning. Thus, this model either
assumes that these factors do not consume capacity, or that they do so but on a fixed per-unit basis
(incorporating it into the per-unit production workload factor).
Gebennini, Gamberini et al. (2009) also develop an integrated production-distribution model to
specify both facility location and product allocation under uncertainty. Using a three-echelon supply
chain (comprised of one central production and distribution center ("CDC"), multiple regional
distribution centers ("RDCs"), and multiple points of customer aggregation), the authors aim to solve
long-term strategic planning, short-term tactical planning, and day-to-day operational planning in an
integrated MILP. According to the authors:
this problem configuration aims to answer three fundamental and interrelated questions:
where is the best place to locate the available facilities, what size is the best capacity to
assign to the generic logistic facility, and when in a specific location demand occurs
requiring a certain amount of production capacity, i.e. the periods of time this capacity is
required (Gebennini, Gamberini et al. 2009).
The key contribution of this paper is the authors' approach to accounting for uncertainty in demand: they
include a factor for safety stock ("SS"), or the minimum amount of inventory that a company seeks to
have on hand to guarantee a certain service level in the face of uncertain demand. As this term grows in
proportion to the square of production, the authors employ a ad-hoc solving procedure in order to keep a
linear cost minimization objective function. This approach is illustrated below:
1. The initial SS cost term is non-linear:
[1]
(ck)2s2 21
L
where: L = set of demand locations; Ck = unit inventory cost/unit time in RDC k; s =
safety factor to control consume service level; a-k, = combined variance at RDC k service the
point of demand 1 ; ogk = binary decision variable, assuming value of 1 if RDC k supplies the
point of demand I in any unit time t, 0 otherwise (Gebennini, Gamberini et al. 2009).
2. However the authors note that the values of binary variable 6Ok that minimize the below linear
equation will be the same as the corresponding .9kl terms that minimize the above non-linear SS
cost at the each RDC:
[2]
(Ck) 2 S2,'l6Ok
L
(Gebennini, Gamberini et al. 2009)
Because Ck, s, and a1k are all constants in Equation [2], this equation is linear with respect to 6 k,,
which, like 19k, is a binary decision variable.
3. Simply substituting this term into the objective function will cause it to underestimate the weights
of the other terms, thus compromising the minimization. To correct this effect, the authors next
divide the term by SSk, which represents the lower bound of the optimal amount of SS carried at
the RDC k. Initially, or for the first iteration i, the authors set SS -= SS) = s * minlt o-l
They then perform a linear optimization, at the end of which they set:
s (ck )2U, 0 if RDC k was utilized in iteration i
Sk L
1 ifRDC k was not utilized in iteration i
(Gebennini, Gamberini et al. 2009)
4. These iterations are repeated until none of the SSW terms are updated, at which point a good
linear approximation of is estimated. The authors then go on to solve the original nonlinear
model, but as this is outside the scope of this thesis, that analysis will not be reviewed in detail.
Gebennini, Gamberini et al. (2009) also apply their model to the distribution network of an Italian
electronics company. In this real case study, the authors find that optimization can yield a 10% saving on
global logistics costs. This savings is the result of an increase in costs on the RDC-customer
transportation leg (34%) offset by significant reductions in CDC-RDC logistic cost, RDC fixed cost, and
SS inventory holding cost (respective savings of 48%, 44% and 19%) (Gebennini, Gamberini et al. 2009).
Corsano and Montagna (2011) further develop the capacity option concept in Thanh, Bostel et al.
(2008) by integrating batch plant design decisions into a typical production-distribution allocation
formulation. Considering a four-echelon supply chain (raw material sites, manufacturing plants,
warehouses, and customer zones), the authors develop a MILP that seeks to minimize total cost define as
equipment cost, operating cost and logistic cost. Equipment cost includes the cost of manufacturing lines
and storage tanks that would enable duplication in or out of phase for a batch manufacturing process
(modeled after the chemical industry). Operating costs include the raw material cost, warehouse
operating cost and production cost and logistics costs include transfer of materials and goods between the
four echelons. One weakness of Corsano and Montagna's approach is the fact that they assume plants
operate in single product campaign ("SPC") mode throughout the time horizon of analysis, an assumption
that does not hold in Amgen's situation.
Corsano and Montagna proceed to solve for the optimal total cost in two manners: (1)
simultaneously, as designed, and (2) sequentially, in which they first solve the production-distribution
problem assuming plant capacities are not constraining and then perform a secondary optimization for the
plant-level investments. Although the second method is likely a closer analogue for typical corporations
that do not do extensive long-range capital planning, the salient point from this study is that it typically
leads to slightly lower logistic costs (6.5-14% reduction depending on echelons) but significantly higher
investment costs (50.5% increase), leading to a total network cost increase of 18.5% (Corsano and
Montagna 2011).
Additional relevant studies were reviewed for comparison but are not examined in detail as the
findings or approach to not uniquely inform this thesis. These sources include Cohen and Lee (1988),
Cohen and Moon (1991), Hodder and Dincer (1986), Tsiakis, Shah et al. (2001), and Zhang, Huang et al.
(2009). The key aspects of these models, as well as those in the above papers, are summarized below in
Table 2.
The MILP described in this thesis aims to incorporate the best aspects of these above studies. As
international shipments and tax issues are relevant to the biopharmaceutical industry, it will seek to
incorporate the approach to duties on shipments outlined in Tsiakis and Papageorgiou (2008), taking this
further to incorporate production-location-specific revenue and profits taxation scenarios. Similar to
Gebennini, Gamberini et al. (2009), the proposed MILP formulation aims to capture the impact of
demand uncertainty on network costs through the estimation of safety stock holding cost. Finally, this
thesis will also leverage the concept of fixed capacity options proposed in Thanh, Bostel et al. (2008) and
further developed in Corsano and Montagna (Corsano and Montagna 2011). Although Amgen is not
currently looking at specific investment decisions, capacity options will be considered from a human
resources perspective, which is equally relevant in this industry.
Model
Structure
Year Case Study #of Network
Echelons Configuration*
2011 Amgen, Inc. 3 RM-PF-RDC
Authors
Author's
approach
Cohen and
Lee
Cohen and
Moon
Corsano and
Montagna
Gebennini,
Gamberini
et al.
Hodder and
Dincer
Shah and
Pantelides
Thanh et al.
Tsiakis and
Papageorgiou
Zhang and
Huang
RM-PF-RDC
RM-PF-D
4 RM-PF-RDC-D
PF-CDC-RDC-D
PF-CDC-RDC-D
4 RM-PF-RDC-D
1988 Example
only
1991 Example
only
2009 Example
only
2011 Italian
electronics
company
1986 Example
only
2001 Example
only
2008 Example
only
2008 Example
only
2009 Hypothet.
shoe mfg
Raw Mat. Production Central Regional
sites plants depots depots
Yes Yes Yes
Yes Yes
Yes Yes
Yes Yes
Customers Raw Products
Materials
Multiple Mutiple
Multiple Mutiple
Yes Multiple Mutiple
Approach Multi- Prod. Safety
period lead time stock
MILP Yes Yes
Multiple
Heuristic
MILP
Yes Yes Mutiple Mutiple MILP
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes
Yes
Yes Yes
Yes Yes
Yes Yes
Yes
Single MILP, Yes
MINLP
Single LP
Mutiple MILP
Mutiple MILP Yes
Mutiple MILP
MILP
Model (cont'd)
Costs Included
Authors Year Case Study Invest- Var. Prod.
ment (units)
Author's
approach
Cohen and
Lee
Cohen and
Moon
Corsano and
Montagna
Gebennini,
Gamberini
et al.
Hodder and
Dincer
Shah and
Pantelides
Thanh et al.
Tsiakis and
Papageorgiou
Zhang and
Huang
2011 Amgen, Inc. Yes Yes
1988 Example
only
1991 Example
only
2009 Example
only
2011 Italian
electronics
company
1986 Example
only
2001 Example
only
2008 Example
only
2008 Example
only
2009 Hypothet.
shoe mfg
Var. Prod.
(lots)
Yes
Prod. Duty/ Transpor- Warehouse Inventory Stockout
Facility Taxes tation /DC Facility Holding Penalty
Yes Yes Yes Yes Yes
Yes Yes Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes Yes
Case Study/ Example
Inclusion and Size of Inputs
Raw Pro- Raw Mat. Prod.
Mat. ducts Sites Plants
6 65 3 2
Central Reg. Demand Time
Depots Depots Zones Periods
2 5
3 2
3 4 6 5 45
Multiple 1 5 >1100 30
Yes Yes
Yes Yes Yes Yes 3 3 18
9 160 5Yes Yes Yes Yes
Yes Yes Yes Yes Yes 6 8
Yes Yes Yes Yes
* RM=Raw Material Site; PF=Produciton Facility; CDC=Central Distribution Center; RDC=Regional Distribution Center; D=Demand Zone, Point or Customer
**1nformation not available in source
Table 2. Production-Distribution Models Reviewed in This Work
PF-RDC-C
RM-PF-D
**
4 Problem Statement and Analytical Approach
4.1 Problem Statement
The purpose of this thesis is to provide an analytical framework for making production decisions for
the formulation and fill manufacturing step (at a strategic high level if not tactical level). Specifically, the
model is designed to analyze how these decisions would change over the 2013-2017 time frame, during
which it is anticipated that i) Site lB will come online as a formulation and fill site and ii) the additional
site referred to as RMS will be brought online. Because Amgen's production-distribution system prior to
this acquisition takes the form of a directed arborescent network,2 each product could only take one path
through the four manufacturing/distribution steps to a customer. The addition of RMS, however, causes
their supply chain to take the form of a directed nonarborescent network, where the set of nodes enable
multiple production scenarios and thus presents an opportunity for optimization (see Figure 5 below).
Fundamentally, developing a form/fill production allocation plan or strategy is about answering a
single question: how many lots ofproduct of a given size should we produce in each facility in each year?
However, this question becomes more complicated when one considers that multiple lot sizes are
available for each product. Additionally, to analyze capacity simultaneously, the situation becomes even
more complex, because this adds the additional question: how many hours of capacity should be
established at each site in each year? Clearly the answer to each question is dependent on the other.
Aside from this dependency, the problem facing Amgen is even more complex due to the number and
variety of unknowns: the number of potential outcomes is a factor of the roughly 75 DP SKUs, each with
2 Arborescent literally means tree-like and directed means that product can only flow in one direction (in this case
from bulk sites to fill/finish sites and finally to distribution centers). Together these terms mean that, viewed in the
direction of allowable product flow, nodes in each echelon following the first (bulk sites) can have exactly one
upstream node and zero or more downstream nodes. The implication of an arborescent structure is that there is only
one path to get any material to any node in the network. Each node in a nonarborescent network, by contrast, can
have multiple upstream nodes, thus the number of ways product can get to each node becomes a factor of the
number of nodes connected to it in each upstream echelon, resulting in a much more complex production allocation
problem.
1-8 frequently used lot sizes matched against 2-3 sites, each with 2-4 potential shift structures (and
associated costs and hours capacity).
Process Trnspot.
For u 0 to Transport.
Logistics stribUtiOn
N. Amer
Dist
Center
Internat .I
Dist
Center
Before AEU Acquisition, Production/Distribution-Allocation is Trivial
Integration of Additional Form/Fill Site Causes Production Allocation Decisions
to Become Complex, Requiring Advanced Modeling for Optimal Solution
Figure 5. Network Representation of Supply Chain, Before and After New Facility Acquisition
All of these factors relating to product decisions or capacity decisions directly or indirectly have a
cost associated with them. Staffing costs will increase once a given staffing level is insufficient to meet
marginal demand requirements. Raw material, transportation lane or tax costs can be considered to be
incurred with the flow of each marginal unit of product. The holding cost of cycle inventory would
depend on the lot sizes produced for each product, and thus would not necessarily rise or fall with an
increase in total demand, as production frequency, but not lot size, would necessarily have to increase to
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meet increases in demand. The holding cost of safety stock, by contrast, is typically assumed to increase
in proportion to the square root of production levels, although in this thesis we will see that this increases
at a slightly faster rate.3 Altogether, it is important to note that cost is directly or indirectly tied to each
factor in this model, and as we are seeking to optimize the decision at hand, our goal will be to minimize
the total of these costs.
3 Safety stock is typical estimated as ZoVL, where Zis the service factor, or the inverse of the standard normal
cumulative distribution for the desired Type I service level (i.e. 2.33 for 99% Type I service level), and ovI is
the standard deviation of unbiased forecast errors for lead time demand. As described in Section 4.3.4 and
Appendix A below, the square root relationship does not hold here and can be better approximated by L08.
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4.2 Methodology
In order to address the challenge of simultaneously optimizing product flows, batch size selection and
capacity levels as described above, a mixed integer linear program ("MILP") was developed. As is
shown below, binary decision variables are necessary in some cases (e.g. facility active flag) and integer
decision variables are desirable (e.g. in the case of deciding a number of batches to produce). Thus an
MILP is preferable to a standard linear program (LP), although selecting the former limits some of the
ways the model can be used to perform sensitivity analyses. Furthermore, every effort was maintained to
keep this model linear in order to limit computational complexity.
As the aim of this thesis is to direct the formulation and fill production allocation decisions of DS->
DP/IDP, rather than the packaging allocation decisions of IDP 4 FDP, the production network in the
MILP is modeled after the diagram in Figure 5 above. Thus, the packaging step will be considered
integral in either the formulation/fill or the distribution process. Following from this, neither the
relatively insignificant production costs nor any logistics costs associated with the packaging process are
included in the MILP. This simplification is reasonable because packaging currently occurs at either Site
1A, which is the current sole formulation/fill plant, or Site 2, which is the primary distribution center for
the international markets. Thus the only exception to this assumption would be product that is filled at
the RMS and then sent to the United States for final distribution. This small amount of product could
either be diverted through Site 1A/B for packaging or packed by a third party contractor at a minimal
incremental cost, and thus our assumption holds.
In consideration of our goal of minimizing cost, the fact that production allocation decisions and
capacity allocation decisions are dependent on one another, and the sheer number of factors under
consideration, we must move beyond traditional analytical tools such as Excel in order to sufficiently
optimize such a model. Given the size of this model, IBM ILOG CPLEX Solver was selected for this
task.
4.3 Mixed Integer Program Formulation
4.3.1 Model Indices and Data Sets
I (i e I) set of products, specifically Inspected Drup Product (IDP) SKUs
J (i eJ) set of formulation and fill facilities in network
L (1 E L) set of distribution centers (DCs) at which points demand will be aggregated
E (e E E) parametrized set of batch size available for each product
S (s e S) set of shift structures available at each facility (e. g. Sday x 24hr x 11ine...)
N (n E N) set of indexed years in analysis (i. e. 1 ... 5 for years 2011 - 2015)
4.3.2 Decision Variables
Xijlen
= lots of DP i, of size e that are to be formulated, filled and finished (FF'd)at facilityj and then
sent to distribution center I for packaging, in year n
Ojsn = boolean for wheter or not shift structure s is implemented at facilityj in year n
f-bijen = boolean for whether or not lot size e is selected for product at facilityj in year n
4.3.3 Optimization Objective Summary
The objective function is comprised of four key terms: (1) the linear variable costs of production, (2)
the variable staffing costs to maintain facilities at a given level of production, (3) the annual variable
holding cost of cycle inventory (raw materials, WIP and finished goods), and (4) the annual variable
holding cost of safety stock. As this is a total cost function, the objective of the model is clearly to
minimize it.
Linear variable costs are defined as the sum of two terms: (1) units produced multiplied by the
variable costs of production and (2) number of lots multiplied by the incremental lot setup cost. Staffing
costs were calculated outside the model for each staffing scenario (see Appendix B for a full discussion),
and are included for all facility-staffing structure combinations that the model implements. Cycle
inventory cost is assumed to be the incremental annual holding cost of one half of the sum of all lot sizes
of unique products produced at a given site. This calculation follows the assumption that inventory is
consumed in an approximately linear manner, so that over time the average amount of inventory of a
given product that a site has on hand is one half of the production lot size of that product. As discussed
above, the safety stock requirement for a given service level, and thus the holding cost of safety stock, is
typically assumed to grow at a rate determined with the square root of demand. In the case of demand for
Amgen's drug product or inspected drug product, however, the appropriate exponent of demand was
empirically determined to be approximately 0.8. The calculation of this exponent is discussed further in
Appendix A.
In developing this objective function and collecting data to populate it, we made every effort to
collect only those costs that are variable, as only these should drive the outcome of the model and
business decisions. For example, since warehouse requirements were unlikely to change for a marginal
increase or decrease in cycle inventory or safety stock, we ignored the warehouse cost term in calculating
total inventory holding costs.
4.3.4 Objective Function
Minimize
Zijen (fije * bij) + r7ij) * Xijien) + [$, linear variable costs]
jsn(l$sn * Kjsn) +
(-r;1 * WACC)*Zijen(f bijen*fije) +
2
Ci; Zijn Xei ((fije * Xijien) 0.8 * LTij 0.6)
[$, staffing costs]
[$, cycle inventory holding costs4 ]
[$, safety stock inventory holding costs] 5
fije = lot size in scenario e for product i at facilityj [units/lot]
bij, = total linear costs per unit to ship to and FF IDP i at facilityj, and then
ship to DC 1 [$/unit]
77ij = incremental lot setup cost for product i at facilityj [$/lot]
"ysn = annual incremental cost of implementing shift structure s
at facility j in year n
rij = replacement cost (incremental value) per unit of IDP i at facilityj [$/unit]
L Tif = production lead time for drug product i at facilityj demanded by dist. ctr. 1
ci; = safety stock holding cost for product i at faciltyj [$/unit]
=Tij * WACC * Zservice level * K
where
4 In both cases of holding costs, warehousing costs are considered fixed (sunk) and ignored. Thus, holding costs
only include the cost of capital invested in inventory.
5 See Appendix A for explanation of 0.8 and 0.6 exponents.
where
WACC = weighted average cost of capital or appropriate discount rate
Zservice level = inverse of the standard normal cumulative distribution function
for the desired service level [dimensionless]
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K =G orecast error of demand(IDP-FDP lead time)0.6 (exp.demand over lead time)0 .8
Using the best available data from the sources described in Section 4.4 below, we collected data to
populated fije, bij, ,ij, and Tij. In calculating ij, we assumed a 2kg loss of drug substance per fill batch
(as is typical of this process), and multiplied this amount by the cost/gram of the drug substance.
Staffing costs are a considerable expense and represent a leading driver of model results under many
scenarios. Each nrn value represents the cost of a feasible shift structure that provides for up to a certain
number of production hours. Because this schedule depends on selectively staffing or not staffing
different production lines, costs do not increase linearly but rather exhibit step-function changes that have
important implications to the model outputs. See Appendix B and Appendix C for a thorough discussion
of this approach.
Throughout the study, we assumed a 10% WACC and a 99% Type I service level, which results in a
Z value of 2.33. Although we developed the model in a robust manner to accommodate various
production lead times, we set LTij equal to 1 month for all products, facilities and distribution centers, as
corresponds to the typical lead times for these products. K in Equation [3] is dimensionless, and, as we
show through an empirical analysis described in Appendix A, is approximately equal to 0.8, which is
constant across all products.
4.3.5 Supply Chain Network Constraints
For convenience of terminology, let Xigii = Ee fije * Xiqlen, or the total amount of production in
units FDP produced.
4.3.5.1 Demand constraint
All demand for all products i at distribution centers I must be fulfilled in each year n, thus:
Zj Xigln > Din vi, 1, n
where D11, = demand for product i in DC I in year n [units/year]
4.3.5.2 Formulation/fill facility capacity constraint
The amount of time consumed (both in changeovers and production runs) in facilityj in year n, must
be no greater than the time available per the chosen shift structure, thus:
iei ((xijen * (ij) + (Xijin/(60 * (;;) 5 s(#jsn * Ojsn) Vj, n
where (ij = lot setup time for product i at facilityj [hours/setup]
(ij = production line speed for product i at facilityj [units/minute]
#7sn = hours available under shift structure s at facilityj [avail hours/year]
Note that unlike the other capacity constrained production-allocations/distribution models discussed
in Section 3.3, this model uses a capacity constraint that takes both lot size and number of lots into
account when determining capacity consumption. Refer to Appendix B for a detailed discussion of how
we calculated these factors, which we performed as a data pre-processing step before the MILP was run.
4.3.5.3 Single shift structure per time period
Each facilityj can only be specified to have one shift structure s in each year n, thus:
Es (jsn) 1 V, n
4.3.5.4 Single lot size selected per facility and time period constraint
For the validity of the cycle stock inventory cost component to hold, as defined, each product i can
have at most one selected batch size e in each facilityj and year n, thus:
Ye f-bijen 1 V i,j,n
4.3.5.5 Risk Mitigation Site maximum production constraint
Per a hypothetical arrangement, RMS would be limited to produce no more than an assumed
percentage of the total demand for any product family in any year. We formulated this constraint as
follows:
[4]
ZiERl Xi,EU,len (allowed %) * LERl Din V R, n (ALTERNATIVE 1)
where R = set of product families, each containing a set of IDP SKU's i
Alternately, we could consider a similar constraint, whereby RMS is limited to a percentage of global
aggregate production, rather than by each product family. In this case, Equation [4] would become:
ZE,l Xi,EU,len (allowed %) * Zi,1 Diln V n (ALTERNATIVE 2)
4.3.5.6 Risk Mitigation Site minimum production constraint
In actuality, per-unit costs (production, logistics, etc.) could typically be higher at either RMS, Site
1A, or Site lB. If this were the case, we would hypothesize that an unconstrained optimization model
might suggest filling/finishing all product at whichever site had the lower cost, as doing so would reduce
fixed costs. Irrespective of this consideration, however, we assume that RMS should be able to ramp up
to full capacity within 3 months of an adverse occurrence at the Site lA/B. This translates to a minimum
product flow constraint through RMS that will keep the facility sufficiently staffed to prepare for a fast
ramp-up. In order to maintain this minimal amount of production at RMS, we determined that it should
produce at least one batch of each product in each year. We formulated this constraint as follows:
le Xi,RMS,len 1 V i,f
4.3.5.7 Within selected lot size constraint
This constraint exists for purposes of the MILP and prevents the program from specifying the
production of any batches where that batch size has not been selected for the given facility and year.
El Xijien M * f-bijen V ij, e, n
4.3.5.8 Minimum production frequency constraint
The concept of minimum production frequency ensures that Amgen will produce enough inspected
drug product ("IDP") with sufficiently long shelf-lives to serve young markets that have an exceptionally
high Remaining Shelf Life ("RSL") requirements on shipped finished drug product ("FDP"). We
formulate this constraint as:
jile Xii,Ico,en ail V i, n
where
[5]
au = min prod frequncy of product i given regulatory constraints of
markets within ICO footprint [ lots = shelf lifej
year] (shelf lifei- maxRSL1 )
In Equation [5], maxRSL1 is the most restrictive remaining shelf life requirement that exists amoung
all of the end customers within the demand zone served by distribution center 1.
4.4 Data Sources
There are two groups of people:
those who can extrapolate from incomplete information
- @ErikBryn (HT: @Delong)
This section provides a high level overview of the data sources and data preparation that was
performed prior to running to model described above. More in depth discussion of specific items can be
found in the Appendices referenced herein.
We acquired product-specific data from a variety of sources, including Amgen's Cognos database
for unit demand forecasts. Rapid Response Bill of Material (BOM) data enabled us to match FDP SKUs
to DP SKUs and thus aggregate demand at the DP level. Rapid Response was also the source of bulk cost
per active gram (DS) and actual cost per unit DP which enabled us to estimate variable production costs
(per an assumption plugged into the model).
We developed capacity options using data from a variety of sources, and the methods for this are
described in detail in Appendix B. We used current facility audits for Site 1A as a baseline for available
hours. From this, we increased or decreased time depending on different shift arrangements for a single
crew per line type (vial or syringe), a single crew per line type plus a shared setup crew, or two crews and
two setup crews. We based approximate facility staffing needs on existing plant headcounts at Site IA
and cost per headcount was provided by the finance group supporting operations. Together this
information was sufficient to provide a set of options and costs for different levels of capacity. For the
different formulation/fill facilities (Site 1B and RMS), we applied factors to both the headcount costs and
line hours available (as each site will have one vile/one syringe line rather than two). These factors are
explicitly defined assumptions that are incorporated into the data pre-processing steps before the model is
run.
We derived production requirements by product from the recent capacity audit performed at Site lA
by members of the operations strategy group. The key elements of this data are available hours (after
deducting for holidays, planned maintenance, etc), production run rates by product and changeover times
by product (including line clear and sterilization steps). As this study was performed on the plant level,
not the line level, we made the simplifying assumption that any available capacity can be utilized to
produce any product. In reality, vial lines and syringe lines are entirely different, which would require
this to be re-examined should such a model be used for plant-level scheduling optimization. In addition
to the audit data, corporate planners for each product provided a list of validated batch ranges for their
respective SKUs. These were indexed from 1-8 and incorporated into the model as index e. In the same
manner as capacity, production requirements from Site 1A were multiplied be factor assumptions for Site
1B and RMS.
Finally, we collected transportation lane data from the transportation group. For each potential
transport lane in the model, this data includes two components: freight cost and shipping container cost.
The predominant shipping container used for long-distance travel is the P-002 bulk shipper. These are a
considerable portion of the overall shipping cost for any lane and, although they are rated for multiple
uses, are often discarded after one shipment. Thus, we assumed that P-002's are fully expensed with each
shipment.
4.5 Model Implementation
4.5.1 Modification to Model for Linearity
As mentioned in Section 4.2 above, we utilized the IBM ILOG CPLEX Optimization Studio, based
on the CPLEX algorithm, to program and run the above model. The CPLEX algorithm is an
implementation of the simplex method in the C programming language, first developed by Robert E.
Bixby and available for commercial purposes in 1988 (Wikipedia 2011). It is important to note that,
although this algorithm is capable of solving integer, very large linear, and convex quadratic
programming problems, it is not capable of solving nonlinear or mixed integer nonlinear programming
problems.
In order to use CPLEX to solve the mixed integer program formulated in Section 4.3 above, we made
some modifications to make this a truly linear programming problem. Recall that the safety stock cost
(one term in the objective function) is defined as:
[6]
cj ((fije * Xijien) 0.8 * LTiji 0.6)
ijn el
Because Xijzen is a decision variable, representing the number of lots of product i of size e that are
produced at fill/finish facilityj for delivery to market I in year n, raising this term to the power of 0.8
causes it, and consequently the entire model, to become nonlinear. LTiji, by contrast is a parameter rather
than a decision variable, thus the exponent of 0.6 is not problematic. In addition, because we set LTijl
equal to one month for all products, this term cancels and is taken out of the subsequent equations below.
In order to preserve the linearity of this model and ability to solve it using CPLEX, a methodology
was developed and tested to implement the above objective function term in a linear manner. First, note
that the safety stock component of the objective function (above) can be rewritten as:
[71
Ci I (fiie * Xiiien) 0.8 (he* Xiiien) 0.2) ~ Cij (fie*i n)
ijn el (fije * Xijlen) iin e l
Although these terms are still nonlinear, note that the numerator alone of the second term is linear.
Thus, the entire term can be made linear if it is rewritten as:
C z(ije * Xijgen
CI 1 0.2
ijn el (Ss)jn J
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where ssi;. = fi*eXijzen
where fi*e is the lot size and xblen is a number of lots of product i, size e, produced at facilityj for
market / in year n, under the optimized scenario. These terms are fixed numbers, and collectively they
prevent the entire safety stock term from underestimating the other terms in the objective function once it
is made linear. An analogous method to that proposed by Gebennini, Gamberini et al. (2009) in Section
3.3 was developed to handle this. We will define the array SS* to be the set of all optimized values of
ssg for all i,j, and n (i.e. SS* (ssE e SS*) ). In order to determine these optimal values, we will
proceed to solve this problem iteratively over multiple iterations k. Letting SS(k) ( E SS (k)) be the
set of all candidate solutions for the optimal set SS* in iteration k, we describe this iterative approach as
follows:
1. For initial iteration k=1, set SS (1 such that fil) * xilen = (mine (fie) * 1) for all products i,
facilitiesj and years n, and f. In other words, assume that the safety stock cost for each product-
site-year combination is the equal to what it would be if only one of the smallest possible batches
were made at this site each year for all markets (independent of which market it is sent to). Thus,
if any product is produced in a given site-year, this initial SSkyn will serve as the denominator.
Otherwise XIwIen = 0, and the safety stock component of this product will equal zero.
2. Solve the MILP with the array of SS(k) values determined in the prior step plugged into Equation
[8].
3. For all products i, facilitiesj and years n, calculate SS(k+l) based on the actual values Xiien
determined by the solution to the k* iteration. For all ij, n, where Zei(xijien) = 0 in the kt
iteration, set SS + = ssi).
4. If SS(k+l) SS(k), return the solution values from the (k-1)* iteration, setting SS* = SS(k), thus
yielding the optimized solution. Otherwise, increment k (k = k +1) and return to step (2).
The above method was first tested for accuracy and effectiveness with a sample dataset comprised of
eight products, each with eight potential lot sizes, three facilities, two markets and five years. Six
iterations were performed to determine the effect this approach had on both the production-distribution
allocation decisions, as well as the total cost function. As can be seen in Figure 6 below, the production
allocation decisions only changed minimally throughout these iterations. More importantly, Figure 7
shows how the total network cost became almost completely stable after the first iteration. This suggests
that, although it requires a first iteration to set the near-optimal values in the SS matrix, once this has been
done, minor changes in production allocation do not have a significant impact on the safety stock
component of total network costs (and an even less significant impact on total network costs per se). For
this reason, it was decided that two iterations will suffice to determine near-optimal safety stock costs
when the model is implemented with the full set of products, facilities, markets and years.
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Figure 6. Production Level at Facilities A and B for Eight Drug Products ("DPs") in Sample Iterations
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Figure 7. Safety Stock and Total Network Costs throughout Sample Iterations
4.5.2 Summary of Model Inputs
After developing an appropriate linearization of the model, the next step was to determine the
appropriate factors and other inputs to run the model. As discussed in Section 4.4, factors were applied to
the values of capacity and production constraints that were measured by the recent capacity audit of Site
IA. A range of values were examined for these parameters in order to understand the sensitivity of the
model to each factor. In addition, various scenarios (in terms of demand level, service level, various
financial/tax implications, opening/closing date restrictions for different sites, and the ability to provide
low capacity staffing structures to sites) were tested in the model. In total, 40 variables were set for a
given iteration, a summary of which is in Table 3 below.
Assumption / Factor Inputs Selected in Various Scenarios
Demand Scenario Pessimistic Base Optimistic
WACC 10%
Forecast Error Variability Factor 0.8
Service Level 95% 99% 99.9%
DSYield Loss per Lot 2kg
Yield Loss Variable Cost 10%
RMS/Site-1A Line Speeds 50% 75% 100%
RMS/Site-1A C/O Times 50% 100% 125%
Site-1B Line Speeds 500 (SYR), 600 (VI
Site-1B/Site-1A C/O Times 125% 150% 200%
Financial Considerations Various Scenarios
Low Capacity Staffing Option Available Not Available
Table 3. Various Inputs Used in Different Implementations of the MILP
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4.5.3 Summary of Scenarios Examined
Following the above, the model was run in IBM ILOG CPLEX Optimization Studio. Full code for
the implementation of the MILP can be found in Appendix F. Seven particular runs were studied in detail
as these highlight some interesting points about the model and production system.
These scenarios were chosen specifically to highlight several points that are interesting from a
managerial perspective. For that reason, many of the potentially variable inputs (e.g. demand scenario,
service level) were held fixed, but particular inputs were changed as indicated in Table 4 below. The
scenarios were chosen to demonstrate the following:
Scenario 1: A base test case, assuming that RMS has slightly slower lines and slower changeovers
("C/O") than Site 1A or Site lB (based on a best guess at time of analysis).
Scenario 2: A modified test case, where the line speed and C/O times are slightly worse. In addition,
this model implemented the effect of a proposed 4% revenue tax that could potentially impact all
product that goes through any production step at either Site 1A or Site lB (O'Grady 2010).
Scenario 3: This scenario implements the same production assumptions as Scenario 1, but it assumes
the revenue tax affects all product flowing out of Site IA or Site 1B (i.e. there is no tax credit for
U.S.-destined product).
Scenario 4: This is a "job shop specialization" scenario, whereby RMS is assumed to have
significantly slower line speeds than the the facilities at Site lA/B (25% slower), but significantly
faster C/O times (50% of Site 1A, 25% of Site 1B).
Scenario 5: This is the highest financial burden scenario. In addition to the full amount of revenue
tax at Site lA/B, this scenario assumes a 10% tax on profits attributable to product formulated
and filled at RMS.
Scenario 6: This scenario removes all of the financial burdens and assumes that RMS is able to
operate in a low capacity mode, where facility staffing arrangements could be flexible and total
staff costs could be reduced.
Scenario 7: This scenario is modeled exactly after the base case inputs of Scenario 1. The only
difference between the two is that the RMS Minimum Production constraint was removed from
the CPLEX model.
Scenario 1 2 3 4 5 6 7*
Operating Assumptions
RMS Avg Line Speed (% of APR-1) 90% 50% 90% 25% 90% 90% 90%
Changeover Time (% of APR-1)
RMS 1.25 1.75 1.25 0.5 1.25 1.25 1.25
Site 1A 1 1 1 1 1 1 1
Site 1B 1.25 1.75 1.25 2 1.25 1.25 1.25
Enable Low Capacity Option 0 0 0 0 0 1 0
Financial Assumptions
Include Tax on RMS Profits 0 0 0 0 10% 0 0
Include APRTaxon NACORevenues 0 0 1 0 1 0 0
Include APR Tax on ICO Revenues 0 1 1 0 1 0 0
*RMS Minimum Production Constraint removed forthis scenario
Table 4. Inputs for Various Scenarions Examined in MILP Model
Per the approach discussed in Section 4.5, each of these scenarios was run once with an initial default
set of SS values, and then a second time with specific SS values as determined in the first run. Typically,
this practice would lead to overall safety stock costs decreasing by approximately 50% in the second
iteration, but with other costs, as well as production allocation decisions, relatively unchanged. The data
discussed in Chapter 5 below is the output of the second iteration, in all cases.
4.5.4 Model Interface
Aside from the seven scenarios discussed in this thesis, the goal of the internship was to create a
flexible model that will enable Amgen to optimize production allocation across their network under
various sets of assumptions and constraints. Section 4.5.2 and Appendix D discuss the parameters that
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can be set for these constraints, but the purpose of this section is merely to give an example of how data
can be fed into and extracted from the MILP running in IBM ILOG CPLEX Solver.
Shown below, Table 5 and Table 6 are example sets of data that are plugged into four different
queries within the source database that the CPLEX Solver will read from. This is a Microsoft Access
Database, and also includes all of the underlying cost, capacity and production requirements data
(collected from various sources at Amgen), as well as all of the logic and data-preprocessing steps
(calculated within the database by multiple queries) to prepare the final set of data for the Solver.
Base Base Base
0.1 0.1 0.1
0.8 0.8 0.8
2.33 2.33 2.33
2 2 2
1 1 1
0.1 0.1 0.1
1 1 1
0 0 0
0 0 0
0.75 0.5 0.9
0 0 0
0 0 1
0 1 1
0 0 0
Base Base Optimistic Pessimistic Base
0.1 0.1 0.1 0.1 0.1
0.8 0.8 0.8 0.8 0.8
2.33 2.33 2.33 2.33 2.33
2 2 2 2 2
1 1 1 1 1
0.1 0.1 0.1 0.1 0.1
1 1 1 1 1
0 0 0 0 0
0 0 0 0 0
0.9 0.9 0.9 0.9 0.9
0.1 0.1 0 0 0
1 0 0 0 0
1 1 0 0 0
0 0 1 1 1
Table 5. Universal Variables Input into MILP Model
Base Base
0.1
0.8
2.33
2
1
0.1
1
0.05
0.05
0.9
0
0
0
0
Base
0.1
0.8
2.33
2
1
0.1
1
0
0
0.9
0
0
0
0
Table: jn Boolean
RMS 2013 0
RMS 2014 1
RMS 2015 1
RMS 2016 1
RMS 2017 1
Site-1A 2013 1
Site-1A 2014 1
Site-1A 2015 1
Site-1A 2016 0
Site-1A 2017 0
Site-1B 2013 0
Site-1B 2014 1
Site-1B 2015 1
Site-1B 2016 1
Site-1B 2017 1
Table:j
RMS 1.25
Site-1A 1
,Site-1B 1.25,
Table: n
2013 0.0275
2014 0.025
2015 0.025
2016 0.01
2017 0
Table 6. Facility-Specific Variables Input into MILP Model
The output of the model is just as important to the usability of this tool to Amgen. The CPLEX
Solver writes raw data (decision variable outputs and objective function calculations) to the Excel
spreadsheet specified in the .dat file (See Appendix F for an exact specification of this file). However this
information is not very useful for managerial analysis in this form. To make this data more readable, we
wrote a macro in Visual Basic for Applicatoins ("VBA") that would automatically perform multiple
calculations on the raw data and output a Pivot Tables containing a presentation of data that is more
useful to management. Table 7 below presents a sample final output with production allocation data
(obfuscated). In addition to this, we the VBA scripts produced an output of total networks cost broken
down by planning year (2013-2017) and type of cost (staff, setup, material, tax, holding costs, etc.). We
chose not to show an example of this output as the format is trivial and the data would have to be
obfuscated.
Row Labels __2013 2014 2015 2016 2017
Drug 1 0% 3% 5% 8% 9%
Drug 2 0% 15% 20% 22% 22%
Drug 3 0% 65% 63% 105% 37%
Drug 4 0% 65% 50% 37% 40%
Drug 5 0% 0% 0% 0% 0%
Drug 6 0% 3% 3% 3% 4%
0% 0% 0% 0% 0%
Facilit Staffn Strurture bYear OBFUSCATED ATA
Row Labels 2013 2014 2015 2016 2017
l RMS
5x24xlRxlS 1 1 1 1
JSite-1B
5x24xlRx] 1 1 1 1
5x24x2RxOS 1
[Value of "1" means given shift structure is selected at site in given year]
Eaclit 1UIlio b Year OBFUSCATED ATA
S s 2013 2014 2015 2016 2017
RIMS 0% 25% 23% 22% 21%
Site-1A 0% 0% 0% 0% 0%
Site-1B 100% 64% 58% 42% 47%
Unit P by Facility. Presentation & Year OBFUSCATED ATA
Row Labelslj6J 2013 2014 2015 2016 2017 Grand Total
i RMS
SYR
Vi
zJSlte-1B
SYR
VI
Grand Total ~ I[, L
Averae Lot 11 b Fill Facility and Year* OBFUSCATED ATA
Row Labels 2013 2014 2015 2016 2017 Grand Total
RMS 96,919 93,472 86,347 87,133 90,917
Site-1B 104,556 121,618 122,279 116,459 127,295 117,288
Grand Total 104,556 110,490 109,300 102,860 108,553 107,248
Comparison of Average Lot Sizes*
2013 2014 2015 2016 2017
Site-1B/RMS 125% 131% 135% 146%
*Unweighted average; based on number of lots only
# of Batches hFac it. Presentation & Year OBFUSCATED ATA
Row Labels AT 2013 2014 2015 2016 2017 Grand Total
- RMS_
SYR
VI
ziSite-1B -1I
SYR
Grand Total
t hS b Faciit. Presentation & Year OBFUSCATED ATA
R 2013 2014 2015 2016 2017 Grand Total
f RMS
SYR 107,975 102,085 89,771 91,091 97,582
VI 81,312 81,312 81,312 81,312 81,312
8 Site-lB
SYR 86,599 88,637 89,165 87,092 96,141 89,283
VI 135,634 198575 199,543 186941 195,835 177,208
Grand Total 104,556 110,490 109,300 102,860 108,553 107,248
Comparison of Average Lot Sizes*
2013 2014 2015 2016 2017
Site-1B/RMS
SYR 82% 87% 97% 106%
VI 244% 245% 230% 241%
*Unweighted average; based on number of lots only
Table 7. Sample Output from MILP Model, as Formatted in Excel
% of Global 1gmand by Product Filled at RVMS OBFUSCA TED DA TA
5 Results and Recommendations
After running the model under various scenarios with a range of input assumptions, we examined and
compared the resulting production/distribution allocation solutions and total network costs. From this
data, we distilled four key findings:
(1) depending on the model inputs, variable staffing costs and financial costs were the two most
predominant factors, but financial costs were most sensitive to assumptions,
(2) despite the large impact of staffing costs, there was typically some amount of excess capacity in
the network,
(3) the fact that staffing and fixed costs led the model not to staff the RMS facility in the one scenario
(7) where is was not explicitly required suggests that the decision to bring RMS online could be
generally attributed to risk mitigation or network expansion rather than only to network cost
optimization, and
(4) batch sizes selected at RMS tended to be smaller than those selected elsewhere.
In response to these findings, we developed the following three recommendations to Amgen Inc.:
(1) the tax implications of all product flows should be incorporated into the final
production/distribution allocation decisions,
(2) it is important to create flexible staffing arrangements/options for the formulation/fill facilities in
order to control total variable network costs and capacity utilization going forward, and
(3) RMS should be optimized for more, smaller batches (when making scheduling or CapEx
decisions) as the model tends to allocate smaller batches for both vial and syringe products to
RMS.
These findings and recommendations are discussed in detail below.
5.1 Magnitude of Staffing Costs and Financial Costs in Model
Perhaps the most salient finding from the seven examined scenarios is how staffing costs and
financial costs dominated total variable network costs captured in the model. As shown in Figure 8
below, staffing costs accounted for approximately 50-90% of total variable network costs. Additionally,
regardless of scenario, it is interesting to note that these costs were fairly constant. In fact, in the first five
scenarios, these costs stayed within 4% of their average. Costs were considerably lower for Scenario 6
(32% below this average), in which a low capacity option was implemented at RMS, and Scenario 7 (48%
below this average), in which the minimum flow constraint to RMS was relaxed.
N Financial Costs
0 Logistics Costs
I Staff Costs
0 Setup Costs
* Holding Costs
1 2 3 4 5
Model Run (w/ Various Inputs)
Figure 8. Total Variable Network Costs by Cost Component under Various Scenarios
Similar to staffing costs, financial costs play a very important role in several of the scenarios
examined. Unlike staffing costs, however, financial costs are much more sensitive to the assumptions that
are used to develop a given scenario. Thus, management should take care to fully understand the
financial impact of any production allocation or distribution decisions, as these could have a major impact
on total variable costs.
6 7
Additionally, we can see from Figure 8 that, overall, logistics costs typically range from 7-12%, or
slightly higher in Scenario 7. Thus, we can see evidence from this model that the biopharmaceutical
industry follows the concept of high value densities as discussed in the analysis of Cooper (1993) in
Section 3.2.
Even more dramatically, setup cost and aggregate holding costs (cycle inventory + safety stock),
despite the care we took to accurately estimate these items, are overshadowed by staffing and financial
costs.
5.2 Staffing Costs and Flexible Capacity
Although one might consider the appropriate tax assumptions as exogenous inputs over which Amgen
has no control, the same is not necessarily true for staffing costs. By contrast, staffing costs are both the
largest most consistent total variable network cost component, and also that over which Amgen might
exercise the greatest amount of control.
Because of this fact, the second piece of information studied in the resulting data from the seven
scenarios was capacity utilization. As shown in Figure 9 below, the average capacity utilization (during
active years) for the three facilities is highly dependent on the chosen scenario. For RMS, capacity
utilization is likely to be very dependent on at least two factors:
(1) the production metrics (e.g. line speed and C/O time) specified at RMS, and
(2) the amount of total production allocated by the model to RMS (assumption).
As we can see in Figure 10 below, which shows the amount of production for each DP type and all
products at RMS under each scenario, the full percentage of maximum allowable production (a value was
assumed) was allocated to RMS under Scenarios 1-4. Presumably tax considerations caused this amount
to decrease from the maximum allowable in Scenarios 5 and 6, and in Scenario 7, in which RMS was not
utilized.
Figure 9. Capacity Utilization and RMS Production Metrics under Various Scenarios
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Figure 10. Production at RMS by Drug under Various Scenarios
Comparing Figure 10 with Figure 9, one can see that varying production metrics between Scenarios 1- 3
(during which RMS produced the maximum allowed amount of global product) led to slight changes in
overall utilization. A more dramatic change in the production metrics was implemented in the "job shop"
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specifications of Scenario 4, in which the capacity utilization at RMS spiked because of the slow line
speeds, despite the very quick C/O times, assumed in this hypothetical scenario.
Despite these varying levels of capacity utilization at RMS in Scenarios 1-4, total staffing costs, as
shown in Figure 8 remain constant. Together these facts suggest that the minimum capacity option, as
currently defined and selected by the model, is sufficient to meet the assumed hypothetical production
demand at RMS. This premise is further supported by Scenario 6, in which a hypothetical low capacity
option is implemented at RMS. The results show a sharp increase in capacity utilization at RMS, and a
significant decrease in total network costs due to savings in staffing costs. For these reasons, it is
recommended that management consider any opportunities that may exist to create flexible staffing
options at RMS.
It is worth further examining the underlying reasons that cause flexible staffing options to be more
effective than facility design/equipment selection in reducing total network costs. In the proposed cost
model, which reflects Amgen's global variable network costs, there are significant step functions with
respect to staffing costs. These are illustrated conceptually in the in Figure 11, an exemplary diagram of
how various cost components change as a function of production level. Some costs, such as logistics
costs or tax costs, can be considered truly variable because they increase incrementally with each
additional unit of production. By contrast, staffing costs, which comprise up to 90% of the variable costs
of the model, are only variable in the long run. As shown in Figure 11, this is because these costs hardly
change at all until specific production thresholds are crossed.6 Beyond each threshold, additional capacity
is required, so a major cost is incurred to step up to the next shift structure level. By the same logic, any
production time savings will not carry to the bottom line unless they result in a step function decrease in a
facilities staffing level. However, at the same time that large increases or decreases in capacity utilization
can have no effect when a company is in the middle of a staffing cost plateau between step function,
6 This is analogous to the capacity options proposed by Corsano and Montagna (2011) and discussed in Section 3.3,
and the same logic is followed in the capacity constraints of the MILP model formulated in Section 4.3.
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being near a step up or down can cause incremental capacity consumption to have a large financial
impact.
Figure 11. Costs as a Function of Production Level
5.3 New Site Creates Value by Mitigating Risks, Adding Flexibility
Scenario 7 points to the relationship between capacity, network resilience, and total costs. In this
scenario, we relaxed the minimum production constraint for RMS (discussed in Section 4.3.5.6) which
requires RMS to formulate and fill at least one batch of every product in every year. The purpose of this
constraint was to ensure that, once online, RMS would retain sufficient expertise and training to be able to
ramp up to 100% of global formulation/fill operations within 3 months of an adverse event that disrupted
production elsewhere. Once this constraint is relaxed, however, RMS is not brought online. Total
network costs are reduced, but so is total network capacity as well as the fundamental resilience of the
network, since it would result in the geographic concentration of formulation/fill activities at Site lA/B.
Based on this analysis, we can derive the conclusion that RMS fulfills risk mitigation rather than only
a network logistics cost optimization function for Amgen. As we can see in Figure 8, the total variable
-+-Capacity
-- Prod Level
- Staff Costs
- Logistics/Tax Cost
- Total Cost
- Cost/Unit
network costs in Scenario 7 are somewhat lower than the corresponding costs in other scenarios. It is
worth noting that these results: (i) are still significantly impacted by the financial/tax assumptions
(partially irrelevant to the fixed cost of bringing RMS online), and (ii) represent variable costs which are
also only a portion of the total network costs (also comprised of a more significant fixed portion).
Nonetheless, in contrast to supply chains where the lower value densities described by Cooper (1993)
might cause logistics costs to drive more of the optimization, the high upfront cost of bringing RMS
online is not significantly offset by lower outbound logistics costs. However, the additional cost of
bringing RMS online could be attributed to both the level of insurance and resilience provided to
Amgen's supply chain as well as the expanded capacity that might enable global expansion, both means
by which Amgen might continue to "ensure continuity of supply" as the Wall Street Journal article
suggested (Gryta 2011).
5.4 Batch Sizing and Small Batch Specialization at RMS
Because capacity utilization and efficient facility operation can have a large financial impact near the
staffing step function points, it is worth noting ways in which this model can inform facility design. In
these situations where a facility may be close to capacity under its current shift structure, facility
efficiency and production metrics can become very important.
With respect to facility design, the key finding from the seven scenarios was that, in general, the
batch or lot sizes selected by the model at RMS were much smaller than those selected at Site 1A or Site
lB. Figure 12 below shows the ratio of average batch size at Site lB to that at RMS, for each
presentation type. Average vial batch sizes at Site 1B range from 140 to 250% of the averages at RMS in
different scenarios. Average syringe batch sizes are even more dramatic, ranging from slightly smaller
than RMS averages to over 300% in size.
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Figure 12. Comparison of Average Batch Sizes (Site 1B/RMS)
The nature of demand in ICO markets leads to two possible drivers of this phenomenon: (1) that
demand is typically for smaller quantities of product and (2) that demand typically calls for longer
remaining shelf lives, which in turn will drive up the required production frequency and drive down the
average batch sizes. Regardless of the reason for this outcome, the clear trend in the data suggests that it
might be reasonable to consider specializing equipment, staffing and training at RMS for a high mix, low
volume (HMLV) mode of operation.
6 Conclusion
6.1 Next Steps and Opportunities for Further Research
The goal of this thesis was not only to create a set of recommendations for Amgen regarding the
production allocation decisions related to the newly-acquired formulation/fill facility, it was also to
develop a methodology and tool with which these decisions could be made under various future scenarios.
Thus, although this research draws its own conclusions, it is also hoped that this will create the
opportunity for greater integration of this approach in the execution of planning decisions at Amgen.
Notwithstanding the above, there are some clear challenges to implementing a somewhat complex
MILP such as the one described in this thesis in the managerial context where little or no prior use of
linear programming for decision support existed. This is not a novel challenge. In a two-decade review
of the evolution of such systems that is now itself 15 years old, Geoffrion and Powers(1995) conclude
that:
optimization-based software for designing distribution systems has been slower than
heuristic software to migrate from mainframe to desktop and slower to develop graphic
user interfaces. Nowadays, logistics executives nearly always choose desktop analytical
software over mainframe software and a GUI over an older style interface, even if it
means accepting a heuristic rather than optimizing package.
Other factors include discomfort with "high" technology when easily understandable
"low" technology appears adequate, inadequate managerial appreciation of the added
benefits of optimization, difficulties in reliably obtaining optimal solutions using
commercial optimization software, and the lingering memory of past failed attempts to do
optimization.
It is possible that all of these influences against the use of optimization, as well as the natural tendency to
prefer the analysis that you can fully understand or that could be repeated ad hoc with tools such as Excel,
will limit the proliferation of this approach at Amgen. Although this will not pose a major challenge in
today's competitive environment, it may in the future when there is a greater amount of competition from
substitute drugs or biosimilars and Amgen is in a position to compete on operational efficiency as well as
drug development and intellectual property. Hopefully the tools and methods suggested in this paper will
be reexamined or perhaps taken closer to broad implementation by another LGO Fellow between now and
that time.
6.2 Conclusion
This thesis presents a rigorously formulated MILP that aims to closely mimic the costs, constraints,
and behavior of the new production system Amgen will have once it brings the RMS and Site 1B online.
The model is specifically designed to capture the cost of different shift structures at different sites, the
tradeoff between lot size and total capacity, tax implications of various scenarios, network logistics costs
and other items that will drive the total cost function of Amgen's production allocation and distribution
decisions.
This model was populated with a mix of actual and hypothetical data based on the best available
information at the time of publishing, and it was run with multiple input assumptions supplied by the
author to see the impact of various hypothetical operational or financial scenarios on Amgen's total costs.
From these scenarios, three recommendations were distilled: Amgen should pay close attention to the
potential financial implications of different production allocation decisions; opportunities for flexible
capacity should be examined at all sites; and equipment and infrastructure should be selected to support
high mix, low volume operations at the RMS.
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Appendix A. Safety Stock Factor Calculation
In order to determine the appropriate level of safety stock (to calculate annual holding costs of this
stock), it is necessary to establish a relationship between aggregate demand, time and forecast errors. As
explained in Rosenfield (1994), this relationship is characterized by the following generalized power rule:
-T,D = K T aDf
where
cYT,D = forecast error for a given product as a function of the length of time period T and
expected demand level D
a,= parameters of relationship
Demand and forecast information were collected for the period of August 2008 forward in order to
estimate both parameters. The collected information represents the majority of Amgen's total demand,
accounting for 71 of 77 DP SKUs and 482 of 556 FDP SKUs (representing 93% of total annual demand
in both cases, in September 2008).
Using 13 forecasts made between 8/1/2008 and 11/1/2009 (matched against actual demand), forecast
errors and their collective standard deviation were calculated for each product at the DP and FDP levels.
It is important to note that demand and forecasts were aggregated over a six-month period for the DP
level, and a one-month period for the FDP level. These selections were based on the average lead time
for production of each product's component. The bulk manufacturing of additional drug substance
("DS") to produce more DP is an involved process that can require six months due to bulk manufacturing
schedules. FDP, however, only requires IDP as a component -the lead time for this can safely be
assumed to be one-month accounting for the FF process and the fact that a significant amount of product
is held in the DS stage (over 99.99% service level, causing this lead time to be independent of DS
production).
Average demand over the same time periods (six months for DP, one month for FDP) was then
calculated using monthly demand data from September 2008 to December 2009. The natural log of
forecast error and average demand for each SKU were yielded and results were sorted by ln(Average
Demand), and then plotted oporecast error against pdemandat the DP and FDP level separately. These results
were then plotted and a linear regression was performed for each graph yielding the p paremters of 0.77 at
the DP level and 0.82 at the FDP level. The results of these graphs and plots are below.
The FDP result is more relevant to the situation studied in this these, as safety stock would be held at
the DP or FDP stage, and re-ordering is equivalent to filling additional batches of DP and inspecting
(typical lead time for this process is one month). Thus we will round and set p=0.8 for purposes of the
model.
Figure 13. P-plot for Drug Product Components
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Figure 14. P-plot for Finished Drug Product
Determining the a parameter was somewhat more involved. This situation was analogous to
that discussed in Vega Gonzalez (2009), and thus a similar approach was followed for each product
family:
1. Where p are time periods with available sales and prior forecast data, define the integer interval7
for samples 1 Y w < max (p)
2
2. Calculate the demand (D) and forecast error (A) within all sample periods of length I.
fj+1
Di = Dy where j = (.-1 +
Pi
Ai= Ap wherep = (pi_1 +
15i
3. Calculate the mean period demand (u) and period forecast error standard deviation (o):
7 Vega Gonzdlez proposed max(p)/2 as the upper limit. In this thesis, w was set to some number of iterations such
that the length of each period (w*p) was at least as long as the lead time for the FDP and so as to maximize the R2
value of the regression described on the following page.
FDP SKUs by 1-Month Forward Forecast
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max(p)
I E g' Di
max (p)
,= StDev(Ai)
4. Plot ln(p) vs. ln(y) and perform a linear regression on the plot. The slope of this linear
regression is the estimate for the a parameter for a given product family.
The results of this analysis, shown in Figure 15 on page 72 reveal some interesting properties of the
different families of drugs. Drugs 1 through 5 are all mature products, and have high R2 values (0.91-
0.99, average=0.96) and low a parameters of 0.36-0.74 (average=0.57). On the other hand, drugs 6 and 8
are much newer products and consequently show high variability based on time, with high R2 values (0.99
in both cases) supporting a estimates of 0.91-0.92. Drug 7 is a different type of molecule and seem to
have a somewhat cyclical trend in forecast errors and was ignored for both reasons. As this study focuses
on long-term strategy, 0.6 is selected as a conservative estimate for mature drugs.
After determining that forecast errors are related to time and demand with the respective parameters
of a=0.6 and P=0.8, the final step is to calculate the value of K that should hold approximately for all
Amgen products. We know that a reasonable model for uncertainty for a variety of lead times and
demand levels is:
[101
UT,D =K TaDf
and thus
[111
K = T,D
-TaDfl
and from the above-described analysis of a and f, we found the appropriate equation for demand of drug
product/inspected drug product (DP/IDP) in Amgen's production process to be:
[121
K T,D
K =
T O.6DO-8
Using data from a variety of different drugs and assuming lead times of one-two months, K was
calculated according to Equation [12]. Although we developed this model in a robust manner to handle a
variety of lead times, we determined that in almost all cases, the typical lead time for the formulation/fill
step (i.e. the lead time that a distribution center ordering product would encounter) was equal to
approximately one month (twenty business days) for all products. Thus T=1 in Equation [12] causing this
factor to become irrelevant. Plugging empirical data from various products into the other terms of
Equation [12] leads to a range of results for K varying from 0.34 to 1.88. Of these results, we found
K=0.8 to be a best approximation to represent the behavior of demand and forecast errors for most drugs
and thus used this value in the MILP model.
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Figure 15. a-plots for Major Product Families
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Appendix B. Detailed Capacity Methodology
Established capacity (Vjs,) is a decision variable representing the number of shifts (or shift structure,
s) scheduled at each FF facilityj in each year n. Each option also has a corresponding annual cost
indicated by the parameter 7rs,.
The capacity decision also leads to hours available (or cpysn) which is treated as a resource consumed
by production. This parameter represents hours available for production after any reductions for
scheduling, planned downtime or OEE (with the exception of changeovers).
Two production activities consume the hours available indicated by a chosen shift structure: setups
and line run time. Correspondingly, rate of consumption is indicated by the following two parameters:
- Lot setup time, or 4,: the hours consumed for line clear, sanitization and setup for each lot of
product i produced at facilityj, given shift structure s.
- Line run speed, or Cy: the units per minute at which product i can be produced at facilityj.
It is worth noting that lot setup time, 4s, depends on the shift structure in place at a facility as well as the
facility. The reasoning behind this follows a recent review of capacity at Site IA (Lehman 2010) which
led to the identification of the following five primary shift structures to be evaluated in this model:
I. available at Site lA (for each VI and SYR, all shifts are 5x24)
1) 2 lines, shared run crew, no setup crew (2Lx1RxOS)
2) 2 lines, shared run crew + shared setup crew (2LxlRxlS)
3) 2 lines, 2 dedicated run crews, no setup crew (2Lx2RxOS)
II. available at Site lB & RMS (for each VI and SYR all shifts are 5x24)
4) 1 line, dedicated crew, no setup crew (1Lx1RxOS)
5) 1 line, dedicated crew, shared (1Lx1Rx1S)
Under options (2) and (5) above, a shared setup crew would be available to perform the line clear,
sanitization and setup functions for two lines. In the case of Site IA, there will be two shared setup
crews, one with responsibility for two VI lines and one for two SYR lines. In the case of Site 1B and
RMS, there will be a setup crew in each location responsible for one VI and one SYR line.
In either of these cases, the presence of the shared setup crew causes the setup to occur independent
of the schedule of the run crew. Thus, from a time consumption perspective, the setup is free. By
contrast, the other options require the run crew to perform the setup, and thus consume line capacity. For
Site IA, this is the case for both the single run crew option (1), and the two run crew option (3) where line
hours available are doubled, but capacity is still consumed for each setup.
Thus, the table of time consumed for each lot setup, 4,, depends on shift structure as well as facility
and product, whereas the table for line run times, (y, only depends on product and facility. The practical
implications of this can be seen in Figure 16 below, where the tradeoffs between run time and changeover
time are seen in light of different staffing scenarios. It is interesting to note that, at all points where
changeovers are as long as average batch run times, having one line crew staffed per line type (i.e. one
vial line run crew and one syringe line run crew, as shown in Figure 16.c), is as efficient as having four
total crews (one each for the two vial lines and two syringe lines, as shown in Figure 9.d). These
equivalence is also shown at the point of intersection on Figure 16.a.
Figure 16. Lot Capacities for Various Run/C.O. Times and Staffing Scenarios
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Appendix C. Example Variable Staffing Cost Calculation
Current fully-burdened salaries for four types of employees (Operations, Process Development,
Quality and General Management) were provided for FY2010 by the finance group. As is shown below
in Table 8, the true numbers have been obfuscated and a 2.5% per annum increase in these costs was
assumed.
Average Wage + Benefits
Annual Wage Incr
Wage Rates
Site
Site-1A
Site-1B
RMS
Site-1A
Site-1B
RMS
2.50%
Year Site-Year
2010 Site-1A-2010
2010 Site-1B-2010
2010 RMS-2010
2013 Site-1A-2013
2013 Site-1B-2013
2013 RMS-2013
Average Wage + Benefits
Ops PD Quality General
$xx $xxx $xxx $xxx
$xx $xxx $xxx $xxx
$xx $xxx $xxx $xxx
$xx $xxx $xxx $xxx
$xx $xxx $xxx $xxx
$xx $xxx $xxx $xxx
Table 8. Estimated Headcount Costs for Future Years by Employee Type [OBFUSCATED]
Next a generic staffing plan, by function, employee type and staffing scenario, was created for each
formulation and fill facility. An obfuscated example of such a plan is included as Table 9 below. A sum-
product was performed on the relevant items in these two tables in order to determine the incremental cost
to provide a given amount of capacity (line-hours) at any facility in any given year. This approach
captures the step-function nature of these costs, which are variable in the long-run but fixed in the short-
run from Amgen's perspective.
Headcount by Site
Indirect HC Factors
PD 0.3
Quality 0.25
General 0.1
Min. 1-Line+
Site-ShiftStruct Crew 1-Line Setup 2-Line
Direct HC 48 90 100 134
SYR Formulation 2 3 3 6
VI Formulation 2 3 3 3
UF/DF 3 5 5 5
SYRSetup 0 - 5 -
SYR Fill 7 14 14 21
VI Setup 0 - 5 -
VI Fill 6 12 12 24
Flex Setup 0 - - -
Flex Fill 0 - - -
Inspect-SYR 5 10 10 10
Inspect-VI 3 5 5 5
Dispensing 2 3 3 6
Tank Wash 4 8 8 16
Transfer Point 3 5 5 10
Component Prep 3 6 6 12
Sanitors 8 16 16 16
Indirect HC 31 59 65 87
PD 14 27 30 40
Quality 12 23 25 34
General 5 9 10 13
Table 9. Generic Facility Headcount Plan by Function and Staffing Scenario [OBFUSCATED]
Appendix D. Data Model Description and Data Collection
a. Data Model: Table used by Optimization Model
The purpose of this section is to outline the skeleton of the data that is needed to populate the Model,
without any reference to how it was collected or aggregated.
The necessary data for the optimization model flows rather naturally from the description of the
constraints and objective function above (as these require input data whereas the output from the decision
variables will come out of the model). The tables of data that will be needed to properly run the model
are as follows:
Index tables: to properly define the dimension of all indices:
- i: the list of all products, identified by a unique key (i.e. DP SKU)
- j: the list of all fill facilities, identified by a unique key such as "Site lA"
- 1: the list of all distribution centers, identified by a unique key such as "LDC"
- n: the list of years to be analyzed in the model such as [2013 ... 2017]
- s: the list of shift structures available, identified by a unique key such as "5x24xlRxOS" 8
Input data tables:
- qry ie:
1. purpose: to provide all of the necessary inputs that vary with combinations of
products i and lots e
2. key columns: [i, e]
3. data items (additional columns): [lot size tagline, lot size (in units)]
4. number of rows = (length of i)*(length of e)
- qryiln
1. purpose: to provide all of the necessary inputs that vary with combinations of
products i, distribution centers 1, and years n
2. key columns: [i, l, n]
3. data items (additional columns): [Demand, RMS tax per unit, Site 1A tax per unit,
DS source is Site 1A (yes/no)]
4. number of rows = (length of i)*(length of f)* (length of n)
- qryjsn
1. purpose: to provide all of the necessary inputs that vary with combinations of
facilitiesj, shift structures s, and years n
2. key columns: U, s, n]
8 This nomenclature means 5 hours/week by 24 hours/day by 1 run crew/line by 0 shared setup crews/every two
lines
3. data items (additional columns): [cost of implementing shift structure, bottleneck line
hours provided]
4. number of rows = (length ofj)*(length of s)* (length of n)
- qryij
1. purpose: to provide all of the necessary inputs that vary with combinations of
products i and fill facilitiesj
2. key columns: [i, j]
3. data items (additional columns): [lot run speed, cost of setup, variable component of
inventory value through fill process, "tau"]
4. number of rows = (length of i)*(length ofj)
- qryijse
1. purpose: to provide all of the necessary inputs that vary with combinations of
products i, facilitiesj, shift structures s, and lot sizes e
2. key columns: [ij, s, e]
3. data items (additional columns): [lot setup time]
4. number of rows = (length of i)*(length ofj)* (length of s)* (length of e)
- qry ijl
1. purpose: to provide all of the necessary inputs that vary with combinations of
products i, facilitiesj, and distribution centers 1
2. key columns: [i, j, f]
3. data items (additional columns): [variable component of inventory value on hand at
distribution center, "b "]
4. number of rows = (length of i)*(length ofj)* (length of t)
- qry iICO
1. purpose: to provide all of the necessary inputs that vary with products i in the ICO
markets
2. key columns: [i]
3. data items (additional columns): [minimum production frequency for ICO market]
4. number of rows = (length of i)
- qry ijnSSk
1. purpose: to hold SS matrix described in Section 4.5
2. key columns: [i, j, n]
3. data items (additional columns): [assumed minimum production level (in units) of
product i at facilityj in year n, raised to the power of 0.2]
4. number of rows = (length of i)*(length ofj)* (length of n)
b. Data Preparation in Excel and Access
The purpose of this section is now to outline the tools and methods that were used to collect and prepare
the data for the Model.
- qry ie:
1. a list of all of the validated batch ranges were collected from the appropriate
Corporate planners (for source data see [Project Root
Folder]\DataCollection\ValidatedBatchRanges)
2. these were consolidated into a single list, given a tagline from 1-8 based on a batch
sizes estimated relative position on a total scale of potential batch sizes (very rough
estimate), and then with the DP SKU and tagline as key columns, entered in the
Model Database as table "ie"
- qryUn
1. Cognos demand was pulled and imported into Model Database as "LE_C_2009"
2. Rapid Response Multi-Level BOM data was pulled to make a best-effort match of all
FDP SKUs to DP SKUs (missing links between the two resolved by asking
Commercial Product managers). The result of this process is the Model Database
table "FDPDPmatchFilteredmTbll." It is important to note that perfection was
not the goal of this match and often times a DP SKU was tied to an FDP SKU
without caring about a DP SKU suffix (e.g. 0183 1B, 0183 IC, and 01831D are all
fundamentally the same filled DP, comprised of the same formulated d-mab - the
only difference is the source of the DS, which is not relevant to this analysis as we
are assuming a single predominant DS source for purposes of determining the
transportation cost to the fill site)
3. "LE_C_2009" and "FDP_DP_matchFiltered_mTbl1" are combined and aggregated
thought a number of queries in the Model Database to result in qryiln.
- qryjsn
1. A model for capacity options and costs was developed in Excel ([Project Root
Folder]/DataCollection/Capacity/jsnModel.xlsx)
2. In this model, 2010 labor and benefits figures for Ops / PD and Quality employees at
Site 1A and Site 2 (proxy for RMS) were provided by David Yapp, and 2.5% annual
increase was assumed.
3. Exact staffing counts by shift structure were estimated and are shown on the sheet
piCalc.
4. For bottleneck capacity, the average of (Effective Production Time + Actual
Changeovers) by year was collected from Peter Pick's recent capacity analysis. This
was assumed to be the capacity of a single line, whereas two lines were assumed to
by twice this number and low-burn was assumed to by %/.
5. Cost and bottleneck hours available are aggregated on the worksheet j sn calc of the
Excel book - fields from this sheet were then populated directly into the Model
Database.
- qryij
1. The following supporting external data tables were collected and entered into the
Model Database
a. xDataBulkCostperAG (source: Rapid Response Inventory Valuation)
b. xDataWAvgActualCost byDP (source: Rapid Response Inventory
Valuation))
c. xDataTransportLanesCosts (source: Gary Hutchinson, see [Project
Folder]\DataCollection\Transportation)
d. xDataUnitSpaceReqs_FINAL (source: Bill Keefe warehousing analysis
with minor additions for missing SKUs based on most similar completed
SKU - see [Project Folder]\DataCollection\UnitSpace-req)
e. xDataConsolidatedRunSetup-new (see [Project
Source]\DataCollection\Capacity\ConsolidatedRunSetup.xlsx)
i. Current run times were collected from Peter Pick's recent capacity
work at Site 1A and entered into the sheet
x_DataConsolidatedRunSetup, and then uploaded into the table
xDataConsolidatedRunSetup new
ii. Site lB was assumed to have 500UPM for SYR and 600UPM for VI.
RMS is assumed to have a factor of the above for all run speeds, as
specified in the Universal Variables table
2. The above external data was combined in the Model Database to yield lot run speeds,
costs of setups and variable cost of inventory for all product and facility
combinations.
- qry #se
1. The following supporting external data table was collected and entered into the
Model Database
a. xDataConsolidatedRunSetupnew (see [Project
Source]\DataCollection\Capacity\ConsolidatedRunSetup.xlsx)
i. Current Changeover times were collected from Peter Pick's recent
capacity work and entered into sheet xDataSite 1AjsCO time,
and then uploaded to the table of the same name in the Model
Database
ii. Change-over factors were entered into the table "j" of the Model
Database for all fill facilities, based on a factor of the above Site 1A
data
2. Within the model database, lot setup times are calculated based on the business rule
that they should be equal to the factored change over time in the event of no shared
crew, or the greater of zero or difference in the change over time and the run time in
the event of a shared crew. These can be shown to be the amount of bottleneck line
time that would be consumed by changeover operations.
- qry ijl
1. This follows the same logic and data sources as qryij, and simply appends the value
of the second transportation leg between the fill site and the distribution center.
- qry iICO
1. Minimum production frequencies, as developed in Section 4, should be added to the
table "i" of the Model Database
- qry ijnSSk
1. Data was extracted from qry_ ie to provide minimum feasible batch sizes by product.
This set was then expanded (multiplied) by all facilitiesj and years n. This base set
of data was then joined with a table of input data (holding 1st iteration x* values) and
the maximum, by i, j and n was taken as the final value.
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Appendix F. CPLEX Implementation
* OPL 12.2 Model
* Author: rlehman
* Creation Date: Sep 1, 2010 at 9:00:25 AM
//Indices
tuple Product toFamily
string DPSKU;
string Family;
}
{Productto_Family} Product = ... ; // i Products
{string} Family = ... ; // m Product family
{string) FillF = ... ; // j Fill facilities
{string} DistC = ... ; // 1 Distribution centers
tuple ProductLotScenario
{
string DPSKU;
string Family;
string LotScenario;
int f;
}
{Product LotScenario} Product Lot = ... ; // e Lot Scenario
{string} ShiftStruct = ... ;
// s Shift structure (e.g. 5x24xLowBurn, 5x24x1, 5x24x2 7x24x2)
{int} Year = ... ; // n Year of analysis
float WACC = 0.1;
// WACC Amgen's weighted average cost of capital assumed in model (10%)
float LIMIT = 0.5;
// LIMIT Limit on amount of global production (overall or by product) that can be
produced at RMS. Set to 0.5 as a default. Set to 1.0 for no limitation.
//Tuple definitions for outputs files
tuple Fill LotAllocation (
// x Cost minimizing product allocation (lots allocated)
string DPSKU;
string LotScenario;
string FillF;
string ShiftStruct;
string DistC;
int Year;
int Value;
tuple FillShiftStructures
// psi boolean, FillF adopts ShiftStruct s
string FillF;
string ShiftStruct;
int Year;
int Value;
float Staff Costs;
}
tuple FillUtilization
string FillF;
int Year;
float Hours Consumed;
float Hours Available;
tuple FillUnitstoMarket
string Product;
string DistC;
int Year;
float Units toMarket;
float D;
tuple Fill EU Prod byFam{
string Family;
int Year;
float EUProd byFam;
float Global_D_by_Fam;
tuple FillCostDetail
string Product;
string FillF;
string ShiftStruct;
string DistC;
string LotScenario;
int Year;
int x;
float eta;
float SetupCosts;
int f;
int Units;
float b;
float UnitVarCosts bye;
float RMS Tax Costs;
float Site lATaxCosts;
float c;
float SafetyStockCosts;
tuple Fill Cycle_InvCosts
string Product;
string FillF;
string LotScenario;
int Year;
float tau;
float WACC;
float CycleInvCosts;
//Input data definition
//by Product, Distribution Center and Year
float D[Product, DistC, Year] = ... ;
// D Denmand for Product i by DistC 1 and Year n
float RMSTax[Product, DistC, Year] = ... ;
// RMStax Calculated in MSAccess, tax to be paid on profits of
products flowing through RMS
float Site 1A Tax[Product, DistC, Year] = ... ;
// Site lA_tax Calculated in MSAccess, tax to be paid on revenues
of products flowing through Site 1A
int DSSource Site lA[Product, DistC, Year] = ... ;
// Indicator for wheter or not bulk manufacturing occurs
in Site 1A (for purposes of calculating Site lA tax burden)
//by Fill Facility, Shift Structure and Year
float pi[FillF, ShiftStruct, Year] = ... ;
// pi cost of staffing FillF j with form/fill ShiftStruct s
in Year n
int phi[FillF, ShiftStruct, Year] =
// phi annual form/fill capacity (in line-hrs) at FillF j
given ShiftStruct s in Year n
//by Product and Fill Facility
float eta[Product, FillF] = ... ;
// eta variable lot setup costs (non-HC, e.g. yield loss in
tank) for each fill lot as FillF j
float xi[Product Lot, FillF, ShiftStruct] = ... ;
// xi lot form/fill setup time (hrs) for Product i at FillF
j
int zeta[Product, FillF] =
// zeta form/fill line run speed for Product i at FillF joat
tau[Product, FillF] = ... ;
// tau sum of upstream, per unit replacement costs (variable
only) were a unit to be scrapped in filling stage
float tau[Product, FillF] = ... ;
// tau sum of upstream, per unit replacement costs (variable
only) were a unit to be scrapped in filling stage
float c[Product, FillF] = ... ;
// c per-unit safety stock holding cost for product i at
facilty j
int SSk[Product, FillF, Year] =
// SSk assumed sqrt(Demand) by product i and facility
k, for purposes of calculating safety stock
//by Product, between Fill Facility and Distribution Center
float b[Product, FillF, DistC] = ... ;
// b sum of per-unit comprehensive variable to FF Product
i at FillF j and ship to DistC L (costs associated with raw materials,
transportation (upstream & downstream) and tax)
//by Product (for ICO Distribution Center)
int alpha[Product] = ... ;
// alpha min production frequency of Product i given constraints of
markets within ICO footprint [lots/year]
//Variable definition
dvar int+ x[Product Lot][FillF][ShiftStruct][DistC][Year]; // x Lots
of Product i filled at FillF j and sent to DistC 1 in Year n
dvar boolean psi[FillF][ShiftStruct][Year]; // psi
Boolean for whether or not shift structure s is scheduled at FillF j in Year n
dvar boolean fb[ProductLot, FillF, Year]; // f_b Boolean for whether
or not lot size e is selected for product at facility j in year n
//ILOG CPLEX settings
execute PARAMS {
cplex.tilim = 1800;
}
execute SETTINGS
settings.displayComponentName = true;
settings.displayWidth = 40;
}
//Objective function definition
minimize
sum( i e in Product_Lot, j in FillF, s in ShiftStruct, 1 in DistC, n in Year
((i_e.f*x[i_e]L[j][s][1][n]) * b[<i e.DPSKU,i e.Family>,j,l]) + //variable (linear)
unit costs, except tax
sum( i e in ProductLot, j in FillF:j=="RMS", s in ShiftStruct, 1 in DistC, n in Year
((i_e.f*x[i-e][j][s][1][n]) * RMSTax[<ie.DPSKU,ie.Family>,l,n]) +
//variable (linear, per unit) taxes on Profits flowing through RMS
sum( i e in Product Lot, j in FillF:j=="Site 1A", s in ShiftStruct, 1 in DistC, n in
Year ) ((i_e.f*x[i_el[j][s][l][n]) * Site 1A_Tax[<ie.DPSKU,ie.Family>,l,n] *
DS Source Site 1A[<ie.DPSKU,ie.Family>, 1, n]) +
//variable (linear, per unit) taxes on Revenues flowing through Site 1A (Site 1A)
sum( i e in ProductLot, j in FillF:j=="Site 1B", s in ShiftStruct, 1 in DistC, n in
Year ) ((i_e.f*x[i_e]L[j][s][1][n]) * Site 1A_Tax[<ie.DPSKU,ie.Family>,l,n] *
DS Source Site 1A[<ie.DPSKU,i-e.Family>, 1, n]) +
//variable (linear, per unit) taxes on Revenues flowing through Site 1A (Site 1B)
sum( i e in Product_Lot, j in FillF, s in ShiftStruct, 1 in DistC, n in Year
(x[i_e][j] [s] [1] [n] * eta[<ie.DPSKU,ie.Family>,j]) +
//variable (linear) lot costs
sum( j in FillF, s in ShiftStruct, n in Year ) (psi[j] [s][n] * pi[j,s,n]) +
//staffing costs
sum( i e in Product_Lot, j in FillF, n in Year ) (f_b[i_e][j][n] * i-e.f *
tau[<ie.DPSKU,ie.Family>][jL] * WACC) / (2) +
//cycle inventory holding costs
sum( ie in ProductLot, j in FillF, s in ShiftStruct, n in Year)
(c[<i_e.DPSKU,ie.Family>] [j] * (sum (1 in DistC) (i e.f*x[i_e] [j] [s] [1] [n])
SSk[<i e.DP SKU,i e.Family>][j] [n]);
//safety stock inventory holding costs
//Constraint definition
subject to {
forall( i in Product, 1 in DistC, n in Year
DistCDemand:
// sum( j in FillF ) (X[i][j][1][n]) >= D[i,l,n];
sum( j in FillF, ie in ProductLot:ie.DPSKU == i.DPSKU, s in ShiftStruct
(ie.f*x[i_e] [j] [s] [1][n]) >= D[i,l,n];
// Units toMarket~i][1][n] >= D[i,l,n];
forall( j in FillF, n in Year)
FillCapacity:
// (sum( i in Product, e in LotScenario, 1 in DistC)
((x[i] [j] [1] [e] [n]*xi[i,j]) + (_X[i]L[j] [1] [n]/(60*zeta[i,j])))) -
(sum( i e in ProductLot, 1 in DistC, s in ShiftStruct)
((x[i_e][j][s][1][n]*xi[i e,j,s]) +
((ie.f*x[i_e][j][s][l][n])/(60*zeta[<ie.DPSKU,ie.Family>,j])))) -
(sum(s in ShiftStruct) (psi[j][s][n]*phi[j,s,n])) <= 0;
// HoursConsumedj][n] <= HoursAvailable[j][n];
forall (j in FillF, n in Year)
SingleShiftStucture:
sum( s in ShiftStruct ) psi[j][s][n] <= 1;
forall (i in Product, j in FillF, n in Year)
SingleLotSizeSelected:
sum( ie in ProductLot:ie.DPSKU == i.DPSKU ) f-b[i_e][j][n] <= 1;
forall (ie in ProductLot, j in FillF, n in Year)
WithinSelected Lot Size:
sum( s in ShiftStruct, 1 in DistC ) x[ie][j][s][1][n] <=
f b[ie][j][n]*999999999;
forall (ie in ProductLot, j in FillF, s in ShiftStruct, n in Year)
Within Selected ShiftStructure:
sum( 1 in DistC ) x[i_e][j][s][1][n] <= psi[j][s][n]*999999999;
I En following section,
// turn on Non EU Min Production and turn off EUMaxProduction,
// or vice versa for different scenarios
//
forall ( i in Product, n in Year:n>=2014)
EUMin Production:
sum( s in ShiftStruct, 1 in DistC, i e in ProductLot:ie.DPSKU == i.DPSKU)
(x[i e] ["RMS"][ s] [1] n]*999999999) - sum(l in DistC) (D[i] [1][ n]) >= 0;
// forall ( i in Product, n in Year)
// Non EU Min Production:
// sum( s in ShiftStruct, 1 in DistC, ie in ProductLot:i e.DP SKU == i.DPSKU)
((xi Ie] ["Site 1A"] Es] [1] [n]+x[i_e] ["Site 1B"] Es] [1] [n)*999999999) >= sum(l in DistC)
Dli][l][n];
// End of section for EUMin Production / NonEUMin Production switch
// In following section,
// turn on EU Max Production and turn off EUMaxProductionbyFamily,
// or vice versa for different scenarios
//
forall (n in Year)
EUMaxProduction:
sum( i e in Product Lot, 1 in DistC, s in ShiftStruct
(i e.f*x[ie]["RMS"]~[s][1][n]) <= LIMIT * sum(i in Product, 1 in DistC) (D[i][l][n]);
// forall (m in Family, n in Year)
// EU_MaxProduction byFamily:
// sum( i e in ProductLot: i e.Family == m, 1 in DistC, s in ShiftStruct
(i e.f*x[i e]["RMS"][s][l][n]) <= LIMIT * sum(i in Product: i.Family == m, 1 in DistC)
(Dli] [][n]);
// EUProdby_Fam[m][n] <= LIMIT * Global_D-by_Fam[m][n];
//
// End of section for EUMaxProduction / EUMaxProduction byFamily switch
forall (i in Product, n in Year)
Min Production Frequency:
sum(j in FillF, s in ShiftStruct, i e in Product Lot:i e.DP SKU == i.DP SKU)
x[ie] [j][ s] ["Site 2"] En] >= alpha[i];
//Output
{Fill Lot Allocation} outFillLotAllocation =
{<i-e.DPSKU,j,s,l,i-e.LotScenario,n, (x[i_e]l[j][s][1]n])>
ji e in ProductLot, j in FillF, s in ShiftStruct, 1 in DistC, n in
Year:x[i_el [j] [s] [1] [n]>O};
{Fill ShiftStructures} outFillShiftStructures = {<j,s,n,psi[j][s][n], (psi[j][s][n] *
piEj,s,n])>
Ij in FillF, s in ShiftStruct, n in Year:psi[j][s][n]>0};
{Fill Utilization) out Fill Utilization = {<j,n,sum( ie in ProductLot, 1 in DistC, s
in ShiftStruct) ((x[ie][j][s][1][n]*xi[i_e,j,s]*psi[j][s][n]) +
((i_e.f*x[i_e][j][s][][n])/(60*zeta[<i_e.DPSKU,ie.Family>,j]))),sum(s in
ShiftStruct) (psi[j] [s] [n]*phi[j,s,n])>
Ij in FillF, n in Year};
{Fill Units to Market} out Fill Units to Market = {<i.DP SKU,l,n,sum( j in FillF, s in
ShiftStruct, i e in Product Lot:i e.DP SKU == i.DPSKU
(ie.f*x[i-e][j] [s] [l] [n]),D[i,1,n]>
li in Product, 1 in DistC, n in Year};
{FillEUProd byFam} outFillEU Prod by_Fam = {<m,n,sum( i in Product: i.Family ==
m, s in ShiftStruct, 1 in DistC) ( sum( ie in ProductLot:ie.DPSKU == i.DP SKU
(i e.f*x[i e] ["RMS"] [s] [l] [n])),sum(i in Product: i.Family == m, 1 in DistC)
(D~i] [l] n])>
Im in Family, n in Year};
{FillCostDetail} out Fill Cost Detail = {<i-e.DPSKU, j, s, 1, ie.LotScenario, n,
x[i_e][j [s][l][n],etaE<ie.DPSKU,ie.Family>][j], (x[i_e][j][s][][n] *
eta[<ie.DPSKU,ie.Family>,j]),ie.f,
i_e.f*x[i_e][j]Es]E1][n],b<ie.DPSKU,ie.Family>][j][l],
(ie.f*x[i_e][j][s][1][n]*bE<i_e.DPSKU,ie.Family>,j,1]),
i_e.f*x[i_e][j]Es][1][n]*RMSTax[<ie.DPSKU,ie.Family>,l,n]*(j==RMS"),
i e.f*x[i_e][j][s][1][n]*Site 1A_Tax[<ie.DPSKU,ie.Family>,l,n]*DSSourceSite
1A[<ie.DP_SKU,i_e.Family>,1,n]*((j=="Site lA")+(j=="Site
1B")),c[<ie.DPSKU,ie.Family>][j],
(c[<ie.DP_SKU,ie.Family>][j]*(i-e.f*x[i-e][j][s][1][n])/(SSk[<i e.DPSKU,i e.Fami
ly>] Ej] [n]))>
li_e in ProductLot, j in FillF, s in ShiftStruct, 1 in DistC, n in
Year:x[i_e] [j] [s] [1] [n]>O};
{FillCycle Inv_Costs} outFillCycle_InvCosts = {<ie.DPSKU, j, i e.LotScenario, n,
tau[<ie.DPSKU,ie.Family>][j], WACC, ((f_b[i_e][j][n] * i-e.f *
tau[<i e.DP SKU,i e.Family>][j] * WACC) / (2))>
1i_e in ProductLot, j in FillF, n in Year:((f_b[i_e][j][n] * i-e.f *
tau[<ie.DPSKU,i_e.Family>][j] * WACC) / (2))>0};
/ *********************************************
* OPL 12.2 Data
* Author: rlehman
* Creation Date: Sep 1, 2010 at 9:00:26 AM
//SheetConnection sheet("AMGNFF_Optv4.xlsx");
SheetConnection output ("output/output 00 NEXT.xlsm");
DBConnection db ("access", "db4_a. accdb");
//Indices
Product from DBRead(db,"SELECT i, DSSKU FROM qryi");
Family from DBRead(db,"SELECT DSSKU FROM qrym");
FillF from DBRead(db, "SELECT j from j");
DistC from DBRead(db, "SELECT 1 from 1");
Year from DBRead(db,"SELECT n from n");
ShiftStruct from DBRead(db, "SELECT s from qry-s");
//Input data
//by Product
ProductLot from DBRead(db,"SELECT i,DSSKU,e,f from qry-iePos");
//by Product, DistC and Year
D from DBRead (db, "SELECT qi,q_DSSKU, q_l,q_n, D_int FROM qryiln");
RMSTax from DBRead(db,"SELECT q_i,qDSSKU,ql,qn,RMS_Tax FROM qry-iln");
Site 1A_Tax from DBRead(db,"SELECT qi,qDSSKU,q_l,q_n,Site 1A_Tax FROM
qry-iln");
DS Source Site 1A from DBRead(db,"SELECT qi,qDSSKU,q_l,qn,iSrc isSite 1A
FROM qryiln");
//by FillF, Shift Structure and Year
pi from DBRead(db,"SELECT j,s,n,pi FROM qry-jsn");
phi from DBRead(db,"SELECT j,s,n,phi_Calc FROM qry-jsn");
//by Product and FillF
eta from DBRead(db,"SELECT ij.i,DS_SKU,j,eta FROM qry_ij");
xi from DBRead(db,"SELECT qryijs.i,qryijs.DS_SKU,e,f,qry ijs.j,s,xi FROM
qry_ijse");
zeta from DBRead(db,"SELECT ij.i,DSSKU,j,zeta FROM qry ij");
tau from DBRead(db, "SELECT i,DS_SKU,j,tau from qryij");
c from DBRead(db,"SELECT i,DSSKU,j,c FROM qryij"); //Calc'd from tau
SSk from DBRead(db,"SELECT i, DSSKU, j, n, SSk FROM qry_ijnSSk");
//by Product, FillF and DistC
b from DBRead(db,"SELECT ijl.i,DS_SKU,ijl.j,l,b FROM qry_ijl");
//by Product (for ICO DistC)
alpha from DBRead(db, "SELECT i,DSSKU,alpha_int FROM qry_iICO");
//Output
//Write fill Shift structures and lot allocations
out Fill LotAllocation to SheetWrite(output,"sol FillAlloc!A2:G9001");
out Fill ShiftStructures to SheetWrite(output,"sol_FillShifts!A2:E9001");
out Fill Utilization to SheetWrite (output, "solFill Util!A2:D9001");
outFillUnitstoMarket to SheetWrite(output,"solFillUnits!A2:E9001");
outFillEUProd byFam to SheetWrite(output,"solFillEUProd!A2:D9001");
outFillCostDetail to SheetWrite(output,"solFillCostDetail!A2:Q9001");
outFillCycleInvCosts to SheetWrite(output,"solFillCycle_Inv_Costs!A2:G9001");
